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Highly sensitive and robust protein assay platforms are urgently needed to improve diagnosis 
and inform therapeutic decisions in many disease areas. However, current bioassays for 
multiplexed protein biomarker detection are plagued by nonspecific antibody cross-reactions, 
which often lead to false positive detection and misdiagnoses. The work presented in this 
dissertation fills this key technological gap in protein assay development, and describes two 
innovative multiplexed bioassays that completely eliminate antibody cross-reactions.  
First, we introduce a multiplexed bead-based assay that not only prevents antibody 
cross-reactions, but also does not require any wash steps. We circumvented the antibody 
crosstalk problem by stably co-localizing antibody-conjugated beads in droplets of immiscible 
aqueous polymer solutions. We demonstrated this assay’s clinical utility by measuring the 
levels of proinflammatory biomarkers (chemokine ligand 9, chemokine ligand 10, interleukin-
6, and interleuikin-8) in plasma samples from from 88 bone marrow transplant (BMT) 
patients. Our assay accurately discriminated BMT patients afflicted with and without chronic 
graft-versus-host disease (GVHD) patients within 2 hours. 
Second, we describe a multiplexed ELISA that eradicates antibody cross-reactions by 
confining and spatially patterning detection antibodies within droplets of phase-separating 
polymers. We used this crosstalk-free assay to measure a panel of four acute GVHD 
biomarkers (tumor necrosis factor-alpha, hepatocyte growth factor, elafin, and ST2) in plasma 





also reduces antibody costs by 100-fold because assays only require 0.5 µl detection antibody 
volume instead of 50 µl required by conventional ELISA. 
Notably, both crosstalk-free multiplexed platforms can be read using commercially 
available plate readers, indicating that these assay platforms can be valuable tools for 












1.1 Importance of Multiplexed Protein Biomarker Analysis 
Protein biomarkers are becoming increasingly essential in clinical research, disease diagnosis, 
and drug development. In clinical research, biomarkers advance our understanding of complex 
disease pathophysiology (Roberts et al. 2006). In oncology, noninvasive biomarker screens are 
used for early cancer detection and diagnosis (Lilja et al. 2008, Kulasingam and Diamandis 
2013). In the pharmaceutical industry, biomarkers are used to evaluate drug safety and efficacy, 
driving ‘go / no go’ decisions in drug development (Khleif et al. 2010). In fact, significant 
improvements in the ability to predict which drug candidates are likely to fail in clinical trials 
saves US $100 million in drug development costs per drug (DiMasi et al. 2003). Recognizing 
these benefits of protein biomarkers, emphasis has been placed on biomarker discovery in many 
disease areas (Wang et al. 2012, Armenta et al. 2009).  
Until recently, it was believed that single biomarkers were sensitive and specific enough 
to reliably detect early-stage disease. For example, an elevated level of prostate specific antigen 
(PSA) is generally indicative of prostate cancer, and is used as a basis to perform prostate 
surgeries. But, only 25% of men who have prostate biopsies due to elevated PSA actually have 
prostate cancer. This means that most prostate surgeries and radiation therapy are due to 
overtreatment, and unnecessarily exposes men to medical complications such as impotence, 





are highly variable among individuals, it is difficult to distinguish between normal and diseased 
individuals based on levels of a single biomarker (Paczesny et al. 2009, Kim et al. 2010). 
Instead, the simultaneous measure of multiple protein biomarkers in single biological samples 
i.e. multiplexed protein detection better evaluate disease complexity and is therefore more 
clinically useful. Unfortunately, several technical challenges limit the widespread use of 
multiplexed protein assays in research, clinical, and pharmaceutical settings. Here, we provide an 
overview of multiplexed protein assays, focusing on these technical limitations. 
 
1.2 Limitations of Current Multiplexed Protein Immunoassays 
The sandwich enzyme-linked immunosorbent assay (ELISA) has been the gold standard for 
immunoassays since its discovery in 1971 (Engvall and Perlmann 1971). Since then ELISAs 
have been applied to multiplexed protein analysis, using planar-based or bead-based technologies 
(MacBeath 2003, Kingsmore 2006).  
In conventional planar assays, capture antibodies are spatially immobilized onto a solid 
substrate (microwell plates or glass slides) in discrete locations. Typically a mixture of detection 
antibodies is added over the entire array as a cocktail and target biomarkers are sandwiched 
between the capture and labeled detection antibodies, eliciting a colorimetric, fluorescent, or 
chemiluminescent signal (Fig. 1.1A). Of these detection methods, only fluorescence-based 
assays can spectrally resolve signals from individual biomarkers because detection antibodies 
can be conjugated to different fluorophores.  In contrast, both chemiluminescent and colorimetric 
immunoassays require spatial separation of signals to achieve multiplexed detection. The main 
drawback of these planar assay formats is the cocktail of detection antibodies, which 





nonspecific binding of detection antibodies, referred to as antibody crosstalk. Therefore, the 
concentration of each detection antibody must be optimized, and costly and labor-intensive 
systematic evaluations of all nonspecific interactions between each antibody and all other 
antibodies and biomarkers must be performed one by one (Gonzalez 2008; Perlee 2004). Due to 
cross-reactivity, some antibodies are removed from a panel, reducing the amount of information 
that can be gathered from the multiplexed biomarker study.  
Bead-based assays consist of microbeads (5.6 µm) coated with capture antibody (Fig. 
1.1B). Protein biomarkers bind to the freely circulating multi-color beads within microwells. 
Like in planar assays, a cocktail of labeled detection antibodies is introduced into the microwell, 
and after washing off unbound antibody, the beads are hydrodynamically focused in a core 
stream of a two-color flow cytometry-like instrument. Beads are excited at two different 
wavelengths (532 nm and 635 nm), exciting both the red/orange fluorochromes inside the beads 
as well as the labeled detection antibodies, thereby identifying and quantifying the detected 
protein biomarker. 
The key advantage of these multiplex bead-based assays is the ability to spectrally 
resolve the signal generated by multiple biomarkers. The drawback is that bead-based assays 
suffer not only from detection antibody crosstalk but also from capture antibody crosstalk 
because the capture antibody-coated microbeads are also suspended in solution, allowing capture 
antibodies to interact. The dominant player in this field is Luminex. In theory, up to 100 different 
microbeads can be distinguished by the Luminex multi-analyte profiling (xMAP) technology. In 
reality, however, 50-plex is the maximum reported for these bead-based multiplexed 
immunoassays because background signals increase and test robustness is significantly reduced 





2012). In addition, variability is dependent on the biomarker measured. For example, interleukin-
2 and interleukin-6 had good correlations (R2>0.95) between two Luminex methods but tumor 
necrosis factor, interleukin-5, and interferon-gamma had poor correlations (Berhoud et al. 2011). 
In addition to poor specificity, both planar- and bead-based assays formats have long assay times 
with numerous wash steps and high sample consumption. These disadvantages stress the 
importance for the need for novel multiplexed technologies that eliminate crosstalk and wash 
steps in a simple, inexpensive, scalable, and flexible format. 
One commercially available singleplex assay, amplified luminescent proximity 
homogeneous assay (AlphaLISA), overcomes most of the limitations of conventional ELISA. 
Benefits of AlphaLISAs include no wash steps, small sample volumes, and wide dynamic ranges 
(> 4 logs). The dynamic range is the range over which there is a linear relationship between the 
biomarker concentration and the assay signal. AlphaLISAs’ broad dynamic range means the 
assay can detect biomarkers from sub-pg/ml to 10 ng/ml whereas conventional ELISAs have 
narrow dynamic ranges (~2 logs). Thus, frequently samples in ELISAs that have target 
biomarker concentrations above the dynamic range must be diluted for the assay. Dilution 
reduces the concentration of the measured biomarkers, making it absolutely critical for assays to 
have pg/ml and fg/ml detection limits. 
In AlphaLISAs, protein biomarkers are sandwiched between biotinylated detection 
antibodies and antibody-conjugated acceptor beads (Fig. 1.2). Then, streptavidin-donor beads 
bind to biotinylated detection antibodies. Laser excitation at 680 nm causes the photosensitizing 
agent (phthalocyanine), contained in the donor beads, to excite ambient oxygen to its singlet 
state. If the donor and acceptor beads are brought within 200 nm by co-recognition of the same 





in amplified luminescent emission at 615 nm (Eglen et al. 2008). However, the major limitation 
of AlphaLISAs is the inability to perform multiplexed protein detection in the current format. 
This inherent disadvantage results because signals generated by the circulating antibody-
biomarker complexes cannot be spatially or spectrally resolved. Innovative methods to multiplex 
highly specific and sensitive, no-wash assays while eliminating antibody cross-reactivity 
between antibodies, will dramatically advance the field of proteomics.  
 
1.2.1. Assay Specificity 
One of the main technical challenges in developing multiplexed protein assays is assay 
specificity. Assay specificity is affected by antibody affinity (the strength of the interaction 
between an antibody and its target antigen) and antibody cross-reactivity (nonspecific binding 
between detection antibodies).  
To detect low abundant target proteins, high affinity antibodies are needed. A low affinity 
antibody for an abundant non-target biomarker may bind equally well as a high affinity antibody 
for a low abundant target biomarker. If this occurs, data generated gives false indications of the 
level of these two biomarkers in the sample. This is particularly problematic because clinically 
useful proteins in blood span a concentration range of 11 orders of magnitude (Anderson and 
Anderson 2002). For example, 50 mg/ml albumin indicates severe liver disease or malnutrition 
whereas > 10 pg/ml interleukin-6 indicates inflammation or infection. Thus, to reliably detect all 
protein biomarkers in blood samples, assays must have dynamic ranges of at least 11 logs. 
Moreover, bioassays should particularly be able to detect proteins at sub-pg/ml sensitivities 
because low abundant cytokines are diluted to femtomolar concentrations when released into the 





Given the diversity in dynamic range of in vivo protein concentrations, it is possible that 
the antibodies used in conventional singleplexed assays are not suitable for multiplexed protein 
assays. Extensive characterization of affinity, specificity, cross-reactivity, and binding kinetics of 
generated antibodies are crucial processes to identify optimum antibodies for multiplexed assays. 
However, these are painstaking processes. Tedious antibody purification methods such as 
dialysis, chromatography, or ammonium sulfate precipitation must be performed to isolate 
antibodies (Grodzki and Berenstein 2010). Next, tests must be done to identify optimal 
antibodies, which have rapid association rates and slow dissociation rates. Recently developed 
antibody affinity microarrays are still in their infancy; hence, current multiplexed assays still use 
the same antibodies as conventional singleplex assays (Poetz et al. 2005; Schwenk et al. 2007).  
Because of the limitations in antibody choice, many multiplexed assays have high detection 
limits. For example, label-free protein detection via surface plasmon resonance (SPR) has 
achieved detection limits of a 0.2 – 2 ng/ml when the SPR signal is not amplified and a few 
pg/ml when the signal is amplified (Ro et al. 2008, Teramura et al. 2006). Similarly, mass 
spectrometry lacks the sensitivity to detect low abundance biomarkers, with limits of detection of 
approximately 2 µg/ml (Addona et al. 2009).  Multiplexed ELISAs usually have detection limits 
between 1 – 100 pg/ml (Kingsmore 2006). Most recently, single-molecule arrays (Simoa) can 
detect as low as 14 fg/ml prostate-specific antigen (PSA) in patient sera (Rissin et al. 2010). In 
Simoa-type assays, samples are compartmentalized into arrays of very small volume chambers.  
While many chambers do not contain any analyte, the few chambers that do contain the analyte 
will have the molecule in such a small volume that the concentration will be higher than in bulk 
solution.  By combining this concentration-by-microcompartmentalization technique with single 





technology currently multiplexes up to 10-plex but suffers from antibody crosstalk and increased 
background signals similar to conventional planar arrays due to the use of detection antibody 
cocktails. The assays also require custom, expensive hardware to perform. 
 While achieving fg/ml detection limits by the Simoa platform is a significant 
technological advancement in multiplexed assays, PSA levels in cancer patients are generally in 
ng/ml concentrations. In addition, as aforementioned, PSA is not good for discriminating 
between diseased and healthy patients. This brings into view a good point – the importance or 
value of detection limits. The limit of detection (LoD) is the lowest analyte concentration that is 
reliably differentiated from the limit of blank (LoB). Specifically, LoB = meanblank + 
1.645(SDblank), and LoD = LoB + 1.645(SDlow concentration sample), where SD is the standard 
deviation (Armbruster and Pry 2008). The ability to measure fg/ml biomarker concentrations is 
only important if the target biomarker is low abundant in patient body fluids. In some cases, like 
graft-versus-host disease, biomarkers such as chemokine ligand 9 (CXCL9) and chemokine 
ligand 10 (CXCL10) are in ng/ml quantities while interleukin-6 and interleukin-8 are in sub-
pg/ml quantities. If the multiplexed assay has a narrow dynamic range or if researchers aim to 
minimize patient sample consumption, samples may be diluted. Upon dilution, concentrations of 
the interleukins may be in the fg/ml range while the chemokines may be in the pg/ml range. In 
this scenario, fg/ml detection of the interleukins is crucial.  
Antibody cross-reactivity arises when detection antibodies bind nonspecifically to 
epitopes of a non-target protein, generating false positive signals (Theilacker et al. 2011) (Fig. 
1.3). This phenomenon is widespread in conventional multiplexed assays because detection 
antibodies are usually introduced into the assay as a cocktail. Furthermore, as the number of 





increases. To mitigate risks of cross-reactivity, tedious systematic evaluations of nonspecific 
interactions between each antibody and each measured protein must be performed one by one 
(Shao et al. 2003; Gaster et al. 2011; Shweitzer et al. 2002; Gonzalez et al. 2008). Even with 
such precautions, assay sensitivity decreases because of high background levels sometimes as 
much as 2- to 5-fold compared to singleplex assays (Kingsmore 2006). Some methods 
circumvent the antibody cross-reactivity problem by performing multiple singleplex tests or so-
called sequential ELISA, where each singleplex test measures only one target protein at a time. 
This time-intensive process has been described in detail (Fiema et al 2012). In another format 
(the direct ELISA), arrayed antigens are used to measure labeled antibodies. But the 
multiplexing ability of this platform is limited because it only reaches detection limits of 100 
ng/ml, which is far too high to measure low abundance biomarkers (Haab 2001). Hydrogel arrays 
require surface modification for gel adherence, hinder diffusion of biomarkers and capture 
antibodies, and are affected by loss of antibody-coated beads within the gel (Ikami et al. 2010). 
Microfluidic approaches are difficult because of complex fabrication, lots of fluidic connections, 
poor reproducibility, and the need for user training (Gaster et al. 2009, Barbee et al. 2010; Li et 
al. 2012; Fan et al. 2008). Antibody co-localization arrays are limited by evaporation of nanoliter 
detection antibody solutions (Pla-Roca et al. 2012). Consequently, emerging technologies that 
use nucleic-acid aptamers are being investigated.  
Aptamers are single-stranded RNA or DNA oligonucleotides 15 to 60 base pairs in length 
that bind with high affinity and high specificity to specific molecular targets. Aptamers are 
advantageous because they are synthesized in vitro with high reproducibility (Hu and Zhang 
2013). One innovative, aptamer-based assay uses Slow Off-rate Modified Aptamers 





technology takes advantage of folded protein-binding pockets as well as the unique nucleotide 
sequence of each aptamer for each target protein (Gold et al. 2010). Aptamer assays are, of 
course, not without their disadvantages. These assays still require multiple wash steps and unlike 
antibodies, the three-dimensional shape of nucleic-acid aptamers is greatly affected by solution 
conditions, limiting the binding of aptamers to target proteins (McKeague and DeRosa 2012).  
 
1.2.2. Matrix Interference 
Another technical challenge that affects the sensitivity of multiplexed immunoassays is matrix 
interference from multiple endogenous antibodies, particularly human anti-animal antibodies 
(HAAAs). Prevalence of these interfering HAAAs in patients may result from an immune 
response that occurs after exposure to animals (e.g. veterinarians, pet owners), blood transfusion, 
and even diets rich in cheese (Hawkins et al. 1980). These circulating anti-animal antibodies can 
reach gram per liter concentrations in the blood (Kricka 1999). They interfere with assay results 
because they form bridges between capture and detection antibodies independently of the target 
protein biomarker, resulting in false positive signals (Figure 1.4A) (Fitzmaurice et al. 1998). 
These HAAAs can also cause false negative signals by preventing target proteins from binding to 
either the capture or detection antibodies (Figure 1.4B). To inhibit HAAA interference in 
immunoassays, plasma samples can be pretreated or diluted in appropriate blocking buffers or 
tubes. One effective blocking buffer is the Heterophilic Blocking Reagent (HBR) from 
Scantibodies Laboratory (Peter et al. 2011, DeForge et al. 2010, Poulsen and Jensen 2007). 
Specifically, the HBR blocks all anti-animal species (anti-rabbit, anti-goat, anti-sheep, anti-
mouse) as well as anti-subtypes of mouse monoclonals (anti-mouse IgG1, anti-mouse IgG2), 






1.2.3. Assay Precision 
Sensitive multiplexed assays should have coefficient of variation (CV) less than 20% 
(Armbruster and Pry 2010). Intra- and inter-assay precision must be evaluated by assaying 
several replicates (< 20) of an identical sample. Ideally, intra- and inter-assay precision will be 
identical, but that is not usually the case because of variation between batches of antibodies, day-
to-day variability, and plate-to-plate variability. Consequently, bead-based multiplex assays 
report intra-assay CVs <15% and inter-assay CVs between 15% and 36% (Liu et al. 2005, 
Prabhakar et al. 2004). 
 
1.3 Aqueous Two-Phase Systems 
In this dissertation, we capitalize on the immiscibility of aqueous polymers to eradicate some of 
the technical limitations of multiplexed protein assays. In this section, an overview of aqueous 
two-phase systems is provided.  
1.3.1. Brief overview of aqueous two-phase systems 
An aqueous two-phase system (ATPS) is formed when two immiscible aqueous polymers are 
mixed in solution, resulting in phases with water content between 80 wt% and 99 wt% 
(Albertsson 1986). The most common ATPS is poly(ethylene glycol) (PEG) and dextran (DEX), 
where the upper phase is constituted primarily of PEG and the lower phase is primarily DEX. 
Phase separation is dictated by differences in hydrophobicity as well as repulsive interactions 





hydrophobic groups on DEX, dextran will become compatible with PEG, making it less likely 
for an ATPS to form. 
 ATPSs are generally used for the gentle separation of biomolecules (proteins, nucleic 
acids), particles, and cells in aqueous environments. Partitioning of biomolecules in an ATPS is 
dependent on several factors, namely the pH, salts, size, molecular weight, and ionic composition 
of the biomolecule as well as the molecular weight of the immiscible polymers. Fortunately, 
there are some general trends observed when partitioning biomolecules within an ATPS: (1) 
reducing polymer molecular weight results in greater affinity for biomolecules to that phase, (2) 
larger particles partition to the interface and DEX, and (3) operating at polymer concentrations 
beyond the critical point (i.e. equivolume phases) increases the partitioning of biomolecules at 
the interface. 
  
1.3.2. Applications of aqueous two-phase systems 
Traditionally, ATPSs were used for cell, protein, and particle isolation and purification on the 
macroscale, as an alternative to centrifugation and liquid-liquid systems. Since then, our lab has 
pioneered the use of ATPS for microscale patterning, particularly for gene silencing and gene 
over-expression, cell co-cultures, and localized sonoporation (Tavana et al. 2009, Yaguchi et al. 
2010, Fang et al. 2012, Frampton et al. 2013). We have also extended the use in microfluidics-
based approaches for aqueous droplet generation (Lai et al. 2011).  Similarly, other labs have 
used ATPSs for synthesizing artificial cells, separating white blood cells from blood samples, 







1.4 Dissertation Overview 
This work will be divided into two main parts. Part 1 describes the main objectives of this 
interdisciplinary thesis research – use of aqueous two-phase systems to develop a no-wash, 
multiplexed, bead-based assay. Part 2 describes the use of ATPSs for other biological 
applications, namely preventing antibody cross-reactions in heterogeneous assays, enabling 
localized sonoporation in vitro, and spatially patterning extracellular matrices. Specifically, 
Chapter 2 demonstrates the utility of ATPSs to spatially pattern matched pairs of antibody-
conjugated beads in discrete microliter dextran droplets. Co-localization of antibody pairs not 
only enabled multiplexing of a no-wash bead assay but also inherently prevented antibody cross-
reactions between different detection antibodies. Detecting and quantifying levels of four 
chemokines and cytokines in cytokine-stimulated human alveolar epithelial cells as well as 
plasma from bone marrow transplant patients validated this innovative multiplexed assay. 
Chapter 3 extends the development of this cross-reactivity-free homogeneous assay by making 
this multiplexed assay user-friendlier. Efforts here were towards reducing user pipetting steps by 
lyophilizing corresponding antibody-bead pairs in dextran droplets in custom 96-well 
microplates. Chapter 4 provides details on the utility of ATPSs to prevent antibody cross-
reactions in heterogeneous multiplexed ELISAs. Next, Chapter 5 provides insights for future 
work, with emphasis on the need for higher plexing levels for biomarker discovery and signal 
transduction applications.  
 In Part 2, Chapter 6 describes how ATPSs can be used to confine ultrasound contrast 
agent microbubbles, enabling localized sonoporation of mammalian cells. Finally, Chapter 7 











Figure 1.2: Schematic showing mechanism of AlphaLISAs. 
 
 
Figure 1.3: Schematic showing different types of antibody cross-reactivity. (A) Ideal sandwich 
assay where matched antibody pairs sandwich target analyte.  (B-D) False positive signals are 







Figure 1.4: Schematic showing how human anti-animal antibodies interfere with immunoassays. 
(A) False positive signals result when interfering antibodies form a bridge between capture and 
detection antibodies. (B) False negative signals result when interfering antibodies bind to capture 
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Antibody Co-localization in Aqueous Two-Phase Systems Enables 
Multiplexed Detection of Disease Biomarkers in Plasma 
 
This chapter describes a multiplexed homogenous immunoassay that co-localizes antibody-
conjugated beads in droplets of immiscible aqueous polymer solutions. This microscale reagent 
patterning strategy forms the basis of a no-wash, multiplexed protein assay that can measure 
proinflammatory chemokines and cytokines from cell culture supernatants and human plasma. 
The assay can be completed in 2 hours with high sensitivity and specificity. Data from this 
multiplexed homogeneous assay correlated strongly with data from conventional singleplex 
amplified luminescent proximity homogeneous assays (AlphaLISAs). Moreover, confinement of 
capture and detection antibody reagent pairs to individual immiscible polymer droplets prevented 
antibody cross-reactions, thereby facilitating robust high-throughput biomarker screening in 











Protein analysis is clinically important for patient stratification and early disease detection as 
well as for research in signal transduction (Paczesny et al. 2009; Kingsmore et al. 2008; Chan et 
al. 2004). The ideal protein assay should be quantitative with high sensitivity and specificity, 
rapid, inexpensive in terms of reagents and sample consumption, and compatible with standard 
lab equipment. The enzyme-linked immunosorbent assay (ELISA) is the most common clinically 
used quantitative protein assay. Because no one biomarker can provide all relevant information 
there is a drive to multiplex such assays.  Multiplexed ELISAs, however, are time-consuming 
because of the need for multiple washing steps, use large sample volumes, and suffer from 
antibody cross-reactions, limiting their usefulness, reliability, and scalability (Theilacker et al. 
2011). Homogenous immunoassays, such as the amplified luminescent proximity homogeneous 
assay (AlphaLISA), simplify assay procedures by eliminating wash steps, increase dynamic 
range, and are faster to perform but typically have limited multiplexing potential because single-
color signals generated by the homogeneously distributed antibody-bead reagents cannot be 
spatially localized or spectrally resolved (Eglen et al. 2008).  Here, we describe the use of 
micropatterned aqueous two-phase systems (ATPSs), composed of the phase-forming polymers 
polyethylene glycol (PEG) and dextran (DEX), to overcome these limitations and enable 
multiplexing of homogeneous immunoassays (Tavana et al. 2009).  
In our approach, complementary pairs of AlphaLISA bead/antibody reagents that target 
specific antigens are co-localized within DEX microdroplets formed within a PEG solution. The 
incorporation of antigens in the PEG phase allows simultaneous delivery of antigens to all DEX 
droplets providing the multiplexing capability.  Importantly, unlike conventional multiplexed 





method localizes detection antibody reagents only to DEX droplets containing complementary 
capture antibody reagents.  This reagent co-localization makes it possible to create spatially 
addressable homogeneous immunoassay arrays where amplified luminescent signals from 
different antigens are spatially resolved and the possibility of unwanted antibody cross-reactions 
are eliminated (Fig. 2.1). The assay method is very simple and an overview of the workflow is 
illustrated in Fig. 2.2. We validated our assay and demonstrated its versatility and clinical use 
potential by detecting 4 proinflammatory chemokines and cytokines, namely C-X-C motif 
chemokine 10 (CXCL10), C-X-C motif chemokine 9 (CXCL9), interleukin-8 (IL-8), and 
interleukin-6 (IL-6)] in cytokine-stimulated human lung carcinoma epithelial cell supernatants 
and plasma from 88 patients who underwent bone marrow transplantation (BMT). We chose this 
validation panel because these proinflammatory agents are typically elevated in chronic graft-
versus-host disease (GVHD) (Croudace et al. 2012; Min et al. 2010; Westekemper et al. 2010). 
GVHD is a long-term, multi-organ disorder that afflicts 30% – 70% of allogeneic BMT patients 
who survive 100 days post-transplantation (Lee 2010).  
 
2.2 Materials and Methods 
2.2.1. Reagents 
Antioxidant-free polyethylene glycol (PEG) (Mw. 35,000) was purchased from Fluka. Dextran 
(DEX) (Mw. 10,000) was purchased from Pharmacosmos. Rhodamine-Dextran (Mw. 10,000) 






2.2.2. AlphaLISA protocol 
Human CXCL10 (AL259C), human CXCL9 (AL280C), human IL-8 (AL224C), and human IL-6 
(AL223C) AlphaLISA immunoassay kits were purchased from Perkin Elmer and performed 
according to manufacturer’s protocol. For cell culture supernatant samples, the assay buffer 
contained 25 mM HEPES, 50 mM NaCl, 10 mM sodium EDTA, 2 mg/ml Dextran (Mw. 
500,000), 0.5% casein, and 0.05% Tween-20, adjusted to pH 7.4. For plasma samples, the assay 
buffer also contained 0.1% bovine gamma globulin (G-5009, Sigma Aldrich) and 0.2 mg/ml 
HBR1 (3KC533, Scantibodies). Standards, biotinylated detection antibodies, and acceptor bead 
solutions were prepared in assay buffer. The assays were performed in 384-well white 
polypropylene conical-bottom microplates (4307, Thermo Scientific). Two microliters of 
standards, cell culture supernatant or plasma sample were incubated with 10 µg/ml acceptor 
beads and 1 nM biotinylated detection antibody for 1 hour at room temperature. Streptavidin-
coated donor beads (40 µg/ml) were added to the mixture and incubated for an additional 30 
minutes. The plate was read on a PHERAstar FS reader (BMG LabTech) where the bead 
complex was excited at 680 nm for 1 second and emission signals were collected at 615 nm for 1 
second after a 40-millisecond delay. 
 
2.2.3. ELISA protocol 
Human CXCL9/MIG duoset (DY392, R&D Systems) ELISA was performed, following 
manufacturer’s specifications. Costar 96 well half-area plates were coated with 6 µg/ml capture 
antibody solutions and stored overnight at 4° C. Plates were washed 4 times with wash buffer 





serum albumin (BSA) for 2 h. Plates were washed another 4 times and then 50 µl recombinant 
protein standard, cell supernatant, or 1:10 diluted plasma sample was added. After 2 h 
incubation, plates were washed again 4 times, incubated with 50 µl of 200 ng/ml detection 
antibody solution for 2 h, washed another 4 times, then incubated with streptavidin-conjugated 
horse radish peroxidase for 45 minutes. Finally, plates were washed 4 times and incubated with 
SuperSignal ELISA Femto Maximum Sensitivity Substrate (37074, Thermo Scientific). 
Chemiluminescent signal was detected using a FluorChem M (Protein Simple) imaging system. 
 
2.2.4. Multiplex ATPS homogeneous immunoassay protocol 
An 18 wt% PEG solution was prepared in 25 mM HEPES buffer containing 0.1% casein. An 18 
wt% DEX was prepared in assay buffer specific to either cell culture supernatants or plasma 
samples. PEG was mixed with standards or sample solutions in a 4:1 volume ratio and the 
mixture was vortexed. For singleplex ATPS assays, 10 µl of the PEG-antigen mixture was 
dispensed into 384-well microplates such that each well contained approximately 2 µl of 
standard or sample and 8 µl of PEG. Acceptor beads (25 mg/ml) and biotinylated detection 
antibody (2.5 nM) were prepared in 18 wt% DEX.  For multiplexed ATPS assays, 100 µl of the 
PEG-antigen mixture were dispensed into each PEG well. DEX solutions, containing acceptor 
beads and detection antibodies against 4 different antigens (CXCL10, CXCL9, IL-8 and IL-6) 
were dispensed into each of the four DEX micro-basins located in the common PEG well. Using 
a multipipettor, 1 µl of the DEX/antibody mixture was dispensed in each DEX micro-basin and 
the mixture was incubated at room temperature for 1 h. To prevent evaporation, the plates were 





the end of the 1 h incubation, 1 µl of the DEX/donor bead solution was dispensed into each 
micro-basin and incubated for an additional 60 minutes. The assays were read on a PheraSTAR 
FS Plus after bead excitation for 1 second.  
2.2.5. Plate fabrication 
Multiplexed ATPS assays were performed in custom plates fabricated from black (Objet 
FullCure 870 Vero Black, Proto 3000) and white (Objet FullCure 830 Vero White, Proto 3000) 
resins using an Objet printer. In this design, white individual DEX micro-basins (2.5 mm x 2.5 
mm x 2.5 mm) were located within a solid black plate matrix (well size 8 mm x 8 mm and 11.5 
mm in height).  Specifically, there are 96 sample wells, each containing 4 DEX microbasins. 
Generally, an all-white plate matrix has better reflectivity to maximize the emission signal, and is 
therefore commonly used for luminescent-based detection.  In contrast, an all-black plate matrix 
absorbs light, minimizing background signals and optical crosstalk. Black plates are used 
primarily for fluorescent-based detection. In our custom plates, white micro-basins were 
designed to maximize amplified luminescent signal. Optical crosstalk was minimized between 
adjacent micro-basins because of presence of the black plate matrix. The micro-basins were 
arranged in a standard 384-well format (24 columns, 16 rows, 4.5 mm spacing) to comply with 
the custom plate specifications of the Society of Biomolecular Screening, and the plate was read 
using a narrow 2.0 mm aperture.   
 
2.2.6. Protein and bead partitioning 
AlphaLISA was used to determine protein partitioning. Solutions containing 2,500 pg/ml antigen 





ml). Control tubes contained 5 µl PBS instead of the antigen. The contents of each Eppendorf 
tube were mixed by vortexing. The tubes were then centrifuged at 400 rcf at 4° C for 15 min. 
After centrifugation, the PEG and DEX phases were separated. Two microliters of the PEG 
phase or the DEX phase were assayed as described above. The partition coefficient was defined 
as the protein concentration in the PEG phase divided by the protein concentration in the DEX 
phase. For partitioning of Omnibeads, 5 µl of the separated PEG and DEX phases was directly 
dispensed into 384-well plates. Since beads contain all chemical components to generate 
luminescent signals, samples were directly excited at 680 nm for 1 second. 
 
2.2.7. Detection antibody partitioning 
Partitioning of the biotinylated detection antibodies was determined by dot blot. Five microliters 
of 500 nM detection antibodies was added to Eppendorf tubes, containing 8.4 wt% PEG and 8.4 
wt% DEX (total volume of contents, 80 µl). Control tubes contained 5 µl PBS instead of the 
detection antibody sample. The contents of each Eppendorf tube were mixed by vortexing. The 
tubes were then centrifuged at 400 rcf at 4° C for 15 min. After centrifugation, the PEG and 
DEX phases were separated. Polyvinylidene fluoride (PVDF) membranes (Bio-Rad) were 
soaked in methanol for 15 seconds, water for 2 minutes, and finally PBS for 5 minutes. 0.3 µl of 
the PEG and DEX phases were dispensed onto the PVDF membranes, and membranes were 
blocked in 1% BSA for 1 h and washed 4 times with PBS containing 0.05% Tween-20. The 
membranes were then incubated with streptavidin-conjugated horseradish peroxidase for 1 h, 
washed 4 times, and incubated with SuperSignal ELISA Femto Maximum Sensitivity Substrate 





(Protein Simple) imaging system. The partition coefficient was defined as the reagent 
concentration in the PEG phase divided by the reagent concentration in the DEX phase. 
 
2.2.8. Cell culture 
A549 human lung carcinoma epithelial cells were maintained in RPMI 1640 supplemented with 
10% heat-inactivated FBS and 1% antibiotics within a humidified atmosphere containing 5% 
CO2 at 37° C. Cells were seeded in 24-well tissue culture plates (8x105 cells per well) 24 h 
before use. At the start of experiments, medium was replaced with complete RPMI supplemented 
with 50 ng/ml IFN-γ, 50 ng/ml TNF-α, or 50 ng/ml IFN-γ/50 ng/ml TNF-α. Cell culture 
supernatants were collected at 0 h, 6 h, 12 h and 24 h.  Recombinant human IFN-γ was purchased 
from Peprotech and recombinant human TNF-α was purchased from R&D systems. 
 
2.2.9. Plasma samples 
Heparinized plasma samples from 88 patients were acquired from a clinical study at the 
University of Michigan between 2000 and 2010. Samples were aliquoted without additives and 
stored at – 80 °C. Of these 88 samples, 20 samples were collected from patients who received 
autologous bone marrow transplantation, 59 samples were collected from patients who received 
allogeneic bone marrow transplantation (GVHD- = 27, GVHD+ = 32), and 9 samples were from 
healthy patients. The institutional review board at University of Michigan approved plasma 
samples collection.  For AlphaLISA and multiplexed ATPS assays, plasma samples were diluted 






2.2.10. Statistical analysis 
Each experiment was repeated in triplicate, using 3 different plates. Results are expressed as as 
mean values +/- standard error of mean.  Graph Pad Prism was used to fit standard curves with a 
four parameter logistic function to calculate sample values.  The limit of detection (LoD) was 
computed as LoB + 1.645 (SDlow concentration sample), where SD is the standard deviation and LoB is 
the limit of blank.  LoB was calculated from LoB = meanblank + 1.645 (SDblank). The linear 
dynamic range (LDR) was calculated as the ratio of the maximum linear response versus the 
LoD (Armbruster et al. 2008). Student’s t-test (two-tailed), one-way ANOVA with the Tukey’s 
post-test, and Pearson’s coefficient of correlation were used to assess significance between 
sample groups and between assay formats. 
 
2.3 Results and Discussion 
2.3.1. ATPS assay design characteristics 
In our custom 96-well microplates (Fig. 2.3A), the DEX droplet size and location were constant 
over the course of the 2 h required to perform the assay (Fig. 2.4A). Each of the 96 wells 
contained four micro-basins for spatial patterning of 2 µl DEX assay droplets (Fig. 2.3B-C). 
ATPSs composed of 18 wt% PEG and 18 wt% DEX were used because these polymer 
concentrations favored antigen and antibody-bead reagent partitioning to the DEX phase, 
ensuring maximum antigen transport into, and retention of reagents within the DEX droplets 
over the course of the assay (Table 2.1). As seen in Table 2.1, regardless of antibody type, all 





CXCL9 antigens in an ATPS composed of higher molecular weight DEX, specifically 5 wt% 
PEG and 6.4 wt% DEX 500. In this ATPS, IL-6 and CXCL9 had partitioning coefficients of 1.33 
and 0.95, respectively. These values are significantly greater than the 0.28 paritioning 
coefficients reported for the DEX (Mw. 10,000) in Table 2.1. These data suggest that small 
chemokines and cytokines partition better to smaller molecular weight DEX, and indicate the 
importance of selecting the correct ATPS system for any given application. 
In addition, increasing DEX concentration generally resulted in higher detection limits of 
singleplex IL-6 ATPS-AlphaLISAs, possibly due to inability of antigens to readily diffuse 
through and bind to antibody-bead pairs in more concentrated DEX (Fig. 2.4B). 
  The optimum assay incubation time was 2 h based on measurement of the 12 pg/ml limit 
of detection (LoD) of IL-6 and the steep gradient of the standard curve (Fig. 2.4C-D).  
 
2.3.2. Comparison of singleplex ATPS and singleplex AlphaLISAs 
Next, we assessed the effect of ATPS on AlphaLISA signals. Standard curves for CXCL10, 
CXCL9, IL-8, and IL-6 were similar in terms of linear dynamic range (LDR) and LoD for 
singleplex ATPS-AlphaLISA and conventional singleplex AlphaLISA (Fig. 2.5A). Moreover, 
the signal-to-noise ratios were comparable between assay formats for all tested antigens, even 
though the ATPS format assays consumed ten times less antibody and bead reagents. The LoD 
and LDR data, along with low statistical variation between measured signals, indicate that the 






2.3.3. ATPS prevents antibody cross-reactions in multiplexed AlphaLISAs 
The importance and effectiveness of using ATPSs to localize antibody-bead reagents and 
generate a reliable signal is demonstrated in Fig. 2.6. In the absence of ATPS, any localized 
reagent dispensing effect is quickly lost by diffusion and convective circulation leading to no 
observable signal anywhere in the presence of 1,000 pg/ml of IL-6. On the other hand, when 
ATPS reagent localization is used, the DEX droplet that contains acceptor beads (AccBs) and 
biotinylated detection antibodies (Abs) bound to streptavidin-coated donor beads generates a 
strong signal whereas the other droplets containing only Ab, only AccB, or no reagent showed 
no signal. When the concentration of IL-6 was increased to 10,000 pg/ml, weak background 
signals were detected everywhere due to reagent crosstalk in the absence of ATPS whereas the 
ATPS assays showed a strong signal only in the droplet with all the required reagents (Fig. 
2.3D). A comparison of standard curves generated by attempting to multiplex AlphaLISA in 
conventional buffer versus curves generated by multiplexing AlphaLISA with ATPS further 
supports the critical importance of ATPS use (Fig. 2.7). 
In some conventional multiplexed ELISAs, the assay sensitivity decreases by as much as 
2- to 5-fold compared to corresponding singleplex assays because of antibody cross-reactions 
and high background signals (Kingsmore 2006). However, in our side-by-side comparison of 
individual singleplex ATPS and multiplex ATPS AlphaLISAs for CXCL10, CXCL9, IL-8, and 
IL-6 in custom 96-well microplates, the standard curves completely overlapped. These data 
indicate that there was no difference in sensitivity caused by antibody cross-reactions or 
increased background signals in our ATPS-multiplexed assays (Fig. 2.8A-D). Moreover, the 
LoD values for proinflammatory cytokines (10.3 pg/ml – 90 pg/ml) and LDR (~ 3 log units) 





precision, as indicated by a coefficient of variation (CV) of less than 25%, is also an important 
consideration for immunoassays. Our ATPS-multiplexed assays had CVs less than 20% (Fig. 
2.8F) (Chau et al. 2008).  
 
2.3.4. ATPS-AlphaLISAs enable multiplexed protein detection in cell supernatants 
One application of our multiplex ATPS assay is monitoring cytokine cascades in stimulated 
cells. Tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) play important roles 
in pulmonary disease (Mukhopadhyay et al. 2006; Koch et al. 2006). We validated our assay by 
measuring 4 proinflammatory cytokines (CXCL10, CXCL9, IL-6, IL-8) in supernatants from 
A549 human pulmonary type II alveolar epithelial cells stimulated with TNF-α and IFN-γ alone 
or in combination (Fig. 2.9). As expected, stimulation with TNF-α or IFN-γ alone did not result 
in a pronounced release of CXCL10 or CXCL9 (Sauty et al. 1999; Pechkovsky et al. 2005). In 
agreement with other studies, our multiplex ATPS assay showed that IFN-γ alone was not 
sufficient to mediate IL-8 or IL-6 release in A549 cells, but that TNF-α alone or in combination 
with IFN-γ could mediate both IL-8 and IL-6 release (Boost et al. 2008; Smart et al. 1994; 
Crestani et al. 1994). In contrast, stimulation with combinations of TNF-α and IFN-γ caused 
dramatic increases in CXCL10, CXCL9, IL-8, and IL-6, although the level for IL-8 was similar 
to TNF-α alone. Figure 2.10 shows correlation curves for CXCL10, CXCL9, IL-8, and IL-6 
between ATPS-multiplexed AlphaLISA and conventional singleplex AlphaLISA. Our ATPS-
multiplexed assay correlates well with singleplex AlphaLISA (n > 33), as indicated by Pearson’s 
correlation coefficients greater than 0.7. We postulate that multiplex ATPS IL-8 assays have the 
weakest correlation (0.7) with conventional AlphaLISA because of the 4 measured cytokines, IL-





assay also correlate well with conventional singleplex CXCL9 ELISA (n = 19), as indicated by a 
Pearson’s correlation coefficients of 0.93 (Fig. 2.12A). 
 
2.3.5. ATPS-AlphaLISAs enable multiplexed GVHD biomarker detection in human plasma 
Finally, we validated our assay for use with clinical samples by measuring the same four 
chemokines/cytokines in plasma from patients who received autologous and allogeneic bone 
marrow transplantation (BMT). Patients who receive allogeneic BMT usually become afflicted 
with chronic graft-versus-host disease (GVHD). Little is known of the pathophysiology of 
chronic GVHD, leading to a lack of effective diagnosis and treatment (Socie et al. 2010). We 
tested the potential use of the ATPS-multiplexed assays for monitoring and diagnosing chronic 
GVHD. In accordance with previous reports, both CXCL9 and CXCL10 were significantly 
elevated in GVHD+ patients compared to GVHD- patients (P < 0.05 by ANOVA), 
demonstrating the potential of these two cytokines as diagnostic GVHD biomarkers (Fig. 
2.11A,B) (Westekemper et al. 2010, Imanguli et al. 2009; Croudace et al. 2012). Specifically, 
GVHD+ patients had mean CXCL9 values of 3,226 pg/ml while GVHD- had mean CXCL9 
values of 843.3 pg/ml. Similarly, GVHD+ patients had mean CXCL10 of 2,463.4 pg/ml while 
GVHD- patients had mean CXCL10 values of 398 pg/ml. However, based on our requirement of 
diluting plasma 1:4 in assay buffer and the sensitivity of AlphaLISA we could not reliably detect 
IL-6 or IL-8 in plasma samples (Min et al. 2001; Tawara et al. 2011). It is also probable that IL-6 
and IL-8 are not significantly elevated in chronic GVHD but only in acute GVHD. Again, the 
ATPS-multiplexed assay data correlated well with singleplex AlphaLISA (Fig. 2.11C,D). 
Similarly, CXCL9 data from our ATPS-multiplexed assay correlated well with singleplex 





values for CXCL10 and CXCL9 between assay platforms (Fig. 2.11E,F).  For both CXCL9 and 
CXCL10, AUC values were greater than 0.8, demonstrating that CXCL10 and CXCL9 
distinguish between patient groups in our multiplex assay. 
The technological specifications for an ideal multiplex protein assay are extensive: assays 
should be sensitive enough to detect antigens within the biological dynamic range; consume only 
small sample volumes; have similar precision to conventional singleplex assays; demonstrate 
high specificity due to lack of antibody cross-reactions; and require only short processing times 
(Kingsmore 2006). Current multiplexed assays, however, do not meet these requirements. As the 
number of antibody pairs in these multiplexed immunoassay increases, the likelihood of 
nonspecific antibody interactions increases exponentially (Gonzalez et al. 2008). To mitigate 
risks of cross-reactivity, tedious systematic evaluations of nonspecific interactions between each 
antibody and each measured protein must be performed to validate these assays (Gonzalez et al. 
2008; Gaster et al. 2011; Schweitzer et al. 2002). Some methods circumvent antibody cross-
reactions by performing multiple singleplex tests (sequential ELISA), where each singleplex test 
measures only one target protein at a time (Fiema et al. 2012). Other methods require surface 
modification, complicated microfluidic approaches or printing of reagents in dry environments, 
which causes reagent evaporation (Li et al. 2011; Gaster et al. 2011; Qin et al. 2009; Pla-Roca et 
al. 2012).  
We eliminated many of these problems with our multiplexed, no-wash, ATPS-
multiplexed AlphaLISAs. Confinement of antibody-conjugated beads within DEX droplets 
prevented the free circulation of beads and enabled, for the first time, multiplexing of 
homogeneous AlphaLISAs. ATPS-AlphaLISAs are inherently designed to prevent antibody 





DEX droplet to another. Because DEX is more hydrophilic and has a lower molecular weight 
than PEG, small cytokines and chemokines in the PEG-sample bath preferentially partition to 
DEX, and so are simultaneously delivered to all DEX droplets. Although non-target antigens can 
also diffuse into the DEX droplets, only target antigens that recognize matched pairs of high 
affinity, high specificity antibodies in DEX will elicit amplified luminescent signals. We 
achieved detection of CXCL10, CXCL9, IL-8, and IL-6 at concentrations of 10.3 pg/ml – 90 
pg/ml in as little as 20 ml of 1:4 diluted plasma with dynamic ranges (2.5 – 3.5 log units) for the 
ATPS assay comparable to singleplex AlphaLISA and greater than most existing multiplex 
ELISA assays (Ikami et al. 2010). Compared to other multiplex bead-based assays, such as 
Luminex, ATPS-multiplexed AlphaLISAs do not require any wash steps nor specialized 
equipment other than a common plate reader to resolve signals from the bead complexes (Liu et 
al. 2005).  In addition, the ATPS-multiplexed assays are scalable because there is no worry of 
antibody cross-reactions or increased background that typically accompanies multiplexed 
immunoassays that use detection antibody cocktails.  Furthermore, in contrast to lengthy ELISA 
or Luminex assays, our assay can be completed in as little as 2 hours.  Finally, we note that the 
ATPS-multiplexed assays reduce AlphaLISA reagent costs by tenfold, from $2.40/well of a 384-
well plate to $0.24/assay droplet.  
 
2.4 Conclusion 
In summary, we have developed and validated a multiplex homogeneous bead-based assay that 
localizes reagents in solution by stable aqueous two-phase system partitioning.  The reagent 
localization feature not only enables multiplexing of homogenous immunoassays but has the 





immunoassays. This is possible because spatial confinement of antibody-conjugated beads in 
ATPS droplets prevents any interactions between different detection antibodies. In other words, 
although we only demonstrate a 4-plex assay, there are little fundamental limitations for higher 
multiplexing. We do note that poor antigen partitioning can affect detection reliability but since 
the formulation for each DEX droplet can be distinct, such issues should be addressable by 
individualizing the DEX formulations, for example by addition of small amounts of DEX 
derivatives or adjusting salt content in DEX (Albertsson 1986). Our highly specific multiplex 
ATPS assay is sensitive enough to detect clinically relevant proinflammatory cytokines in both 
cell culture supernatant and plasma samples with minimal matrix interference. In addition, our 
no-wash assays enable researchers to detect a panel of proteins in only 2 hours while using small 
volumes of biological or clinical samples. With more extensive validation on larger patient sets, 
this ATPS-multiplexed assay is envisioned to be useful not only in research settings but also as a 













Figure 2.1: Schematic representation of ATPS-enabled multiplexed AlphaLISA. (A) 
Conventional AlphaLISA assays can perform no-wash singleplex antigen detection with wide 
dynamic ranges but cannot be multiplexed because antibody-bead complexes freely diffuse and 
circulate in the assay wells, making it impossible to resolve single-color luminescent signals 
from multiple biomarkers. Also the antibody-bead complexes may crosstalk (red circle), 
resulting in false positive detection. (B) In ATPS-multiplexed AlphaLISA, antibody-bead 
complexes are spatially confined in dextran droplets and biomarker specific readouts are 







Figure 2.2: Schematic of workflow for ATPS-multiplexed homogeneous assay. (A) Samples, 
containing antigens, are mixed with PEG. (B) DEX droplets (1 µl), containing corresponding 
antibody-acceptor bead pairs are spatially dispensed into the bulk PEG phase. (C) During a 1-
hour incubation, antigens diffuse from PEG into the DEX droplets, and bind to antibody-beads. 
(D) DEX droplets (1 µl), containing streptavidin-coated donor beads are introduced into the 
solution and incubated for another hour. Donor beads bind to biotinylated antibodies, eliciting 







Figure 2.3: Custom microplates for ATPS-multiplexed assays. (A) A photograph of the custom 
96-well microplate. Each of the 96 wells contains four white micro-basins for stabilizing four 
patterned dextran droplets within the black plate matrix. (B) A cross-sectional diagram of the 
custom plate showing micro-basins for DEX droplet stabilization. (C) A top-view diagram 
depicting the configuration of Ab-AccB complexes as used for the cross-reaction analysis in D. 
(D) In the presence of ATPS, background levels were low, no cross-reactions were observed, and 
maximum luminescent signal was detected only when both Ab & AccB were dispensed into the 
same microbasin (black bars). But in the absence of ATPS, background levels were high and 
significant cross-reactions occurred (grey bars) (*P < 0.05 by one-way ANOVA and Tukey’s 
post-test). AlphaLISA signal was normalized to control experiments where the buffer or DEX 
respectively did not contain spiked IL-6. Error bars represent mean values ± SEM, over 3 








Figure 2.4: Optimizing ATPS assay incubation time. (A) Time lapse showing dextran droplet 
stability in the custom plates over the course of 3 hours at room temperature. Scale bar, 500 mm. 
(B) Mean limit of detection for singlplex IL-6 ATPS-AlphaLISA as a function of DEX (Mw. 
10,000) concentration. (C) Mean limit of detection values for singleplex IL-6 ATPS-
AlphaLISAs as a function of total assay time. The means were not significant upon analysis by 
one-way ANOVA and Tukey’s post-test. (D) Standard curves for singlplex IL-6 ATPS assays 
indicate that 2-hour assay times have greatest AlphaLISA signal counts. Error bars represent 





Table 2.1. Partition coefficients of antigens and antibody-bead reagents in ATPS. Antigens and  
antibody-bead reagents partition to DEX in our ATPS assays. The partition coefficient (Kpart) 














CXCL10 Goat polyclonal 0.23 0.09 -- 
CXCL9 Goat polyclonal 0.30 0.28 -- 
IL-8 Mouse monoclonal 
Protein A purified 
0.07 0.64 -- 
IL-6 Rat monoclonal 0.18 0.28 -- 





Figure 2.5: Comparison of limit of detection (LoD) and linear dynamic range (LDR) for 
singleplex ATPS assays (2 µl reagents) and conventional singleplex AlphaLISAs (20 µl 
reagents) (A-D). (E) Quantification of LoDs and LDRs. Error bars represent means ± SEM. The 
tenfold decrease in required antibody-beads accounts for the overall reduced AlphaLISA signal 
in the ATPS assays. Consequently ATPS standard curves are shifted downwards from the 
AlphaLISA curves in. However, the signal-to-noise ratios are comparable between both assay 






Figure 2.6: ATPS-multiplexed assays confine antibody-bead reagents and prevent reagent cross-
reactions. (A) In the absence of ATPS, detection antibodies (Ab), acceptor beads (AccB), and 
donor beads freely circulate in assay buffer. (B) In the presence of ATPS, Ab, AccB, and donor 
beads remain localized in DEX droplets while antigens diffuse from the bulk PEG phase into 
DEX droplets. (C) In the absence of ATPS, droplets containing Ab only, AccB only or no 
reagent generated luminescent signals similar to the signal detected when both Ab and AccB 
were dispensed into the same microbasin (grey bars) (n.s. by one-way ANOVA and Tukey’s 
post-test). But spotting Ab, AccB, and donor beads in DEX, confined the reagents at the correct 
working concentrations in the micro-basins, producing the expected level of luminescent signal 
for 1,000 pg/ml IL-6, without any enhancement of signal for the Ab only, AccB only or the 
Empty cases (black bars) (*P < 0.05 by one-way ANOVA and Tukey’s post-test). Error bars 







Figure 2.7: Co-localizing bead-based reagents in ATPS droplets is necessary to perform 
multiplexed homogeneous assays. (A) Protein levels in standard ladder decreased (IL-6 and 
CXCL9) while CXCL10 and IL-8 levels increased. (B) Higher background levels were noted in 
the multiplex standard curves in buffer only (no ATPS), indicating significant antibody cross-
reactions. In contrast, lower background levels were observed when antibody-bead reagents were 
co-patterned in DEX (ATPS), validating the lack of antibody cross-reactions in ATPS-







Figure 2.8: Correlation between ATPS-singleplexed and –multiplexed AlphaLISAs for four 
proinflammatory cytokines: (A) CXCL10, (B) CXCL9, (C) IL-8 and (D) IL-6. (E) Sensitivity of 
cytokine detection between singleplex and multiplex ATPS assays (p-values calculated by two-
tailed t-tests). (F) Mean intra-assay CVs for ATPS-multiplexed AlphaLISA. Data in A-D were 







Figure 2.9: Dose and time-dependent effects of TNF-α and IFN-γ stimulated A549 cells on the 
release of proinflammatory cytokines: (A) CXCL10, (B) CXCL9, (C) IL-8 and (D) IL-6. Cells 
were stimulated at the indicated times with 50 ng/ml TNF-a (TNF50) alone, 50 ng/ml IFN-γ 
(IFN50) alone, or 50 ng/ml IFN-γ and 50 ng/ml TNF-α (IFN50 + TNF50). Protein levels 







Figure 2.10: Correlation of measured values between the ATPS-multiplexed and conventional 
AlphaLISA assays for (A) CXCL10, (B) CXCL9, (C) IL-8, and (D) IL-6 in cell culture 
supernatants. Correlation is reported using the Pearson r correlation coefficient. Error bars 






Figure 2.11: Multiplexed protein measurements in plasma of patients who had undergone bone 
marrow transplantation. (A, B) Mean values of CXCL10 and CXCL9 concentrations from 88 
healthy, autologous, no GVHD, and chronic GVHD patients measured by ATPS-Multiplexed 
AlphaLISA assays. Samples were measured in triplicate on one plate and in 3 independent 
experiments. Both CXCL10 and CXCL9 were significantly elevated in GVHD+ patients 
compared to all other patient groups (*P < 0.05 by one-way ANOVA and Tukey’s post test) (C, 
D) Correlation of measured values between the multiplex ATPS assay and conventional 
AlphaLISA for plasma samples. Correlation of protein levels in clinical patient plasma for 
CXCL9 and CXCL10 are reported using the Pearson r correlation coefficient. (e-f) Receiver 
operating characteristic (ROC) curves comparing CXCL10 and CXCL9 concentrations in 
patients without GVHD and patients with GVHD. ROC curves for ATPS-Multiplexed 
AlphaLISAs are compared to ROC curves obtained from singleplex AlphaLISA. All error bars 










Figure 2.12: Correlation of measured CXCL9 values between the ATPS-multiplexed 
AlphaLISA and conventional singleplex ELISA for (A) cell culture supernatants and (B) plasma 
samples. Correlation of protein levels in clinical patient plasma for CXCL9 is reported using the 
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Aqueous Two-Phase System Patterning for Crosstalk-free, Multiplexed, 
Heterogeneous Enzyme-Linked Immunosorbent Assays  
 
This chapter describes the use of aqueous two-phase systems to prevent the antibody crosstalk 
problem – the key limitation of current multiplexed heterogeneous immunoassays. Detection 
antibodies were spatially localized in aqueous microdroplets. Data from this crosstalk-free 
multiplexed ELISA correlated strongly with data from conventional singleplex ELISAs. Notably, 
these innovative crosstalk-free assays allow robust multiplexing of any reliable singleplex 
ELISA. Therefore, there is no need to cross-validate reagents every time new candidate 















Protein biomarkers assess the physiological state of the human body and their concentrations 
change as a result of microbial infection, inflammation, or malignancy. Hundreds of potential 
disease-specific biomarkers have been reported; however because of the complexities of the 
body, individual biomarkers cannot truly identify many diseases (Vasan 2006; Paczesny 2009). 
Thus, there is a need for simultaneous protein biomarker analysis, or so-called multiplexed 
biomarker assays. Many multiplexed biomarker tests exist but these tests suffer from the 
nonspecific binding of detection antibodies to non-target biomarkers, i.e. antibody crosstalk. 
Antibody crosstalk increases assay background levels, reduces sensitivity, limits quantification 
accuracy, and increases false positive signals. Technological advances that eliminate antibody 
crosstalk in multiplexed biomarker tests will inevitably overcome these inherent test limitations. 
We have eradicated the problem of detection antibody crosstalk by using an aqueous two-
phase system (ATPS) composed of polyethylene glycol (PEG) and dextran (DEX) to confine 
detection antibodies to regions where the corresponding capture antibodies are patterned (Tavana 
et al. 2009, Tavana et al. 2010, Frampton et al. 2013). This new method, referred to as ATPS-
ELISA, works on three principles: 1) droplets of the denser DEX solution sink in the PEG 
solution and remain in contact with the assay plate during incubation; 2) interfacial tensions 
between DEX-PEG and DEX-assay plate cause the DEX droplet to assume a dome shape that 
remains in place; and 3) antibodies are retained in the DEX phase due to partitioning effects, i.e. 
they are less susceptible to diffusion from their original location. We demonstrate that this 
approach is effective at simultaneously detecting at least four different chemokines and cytokines 
associated with acute graft-versus-host disease (GVHD), a disease that requires multiple 





2010). Our measurements were free from antibody crosstalk and required less antibody and 
patient sample than conventional ELISA. 
 
3.2 Materials and Methods 
3.2.1. Reagents 
ATPSs were prepared from DEX solutions of various molecular weights and concentrations (10 
kDa and 500 kDa (Pharmacosmos), and 40 kDa (Sigma)), with 35 kDa PEG of various 
concentrations (Sigma).  Phycoerythrin-conjugated mouse anti-human CD184 IgG2α (cat # 
555974, BD Pharmingen) and 500 kDa fluorescein-dextran (cat # D7136, Molecular Probes) 
were used to assess droplet stability and antibody localization over time. ELISA kits for human 
sTNFR1 (cat # DY225), human IL-2 Rα (cat # DY225), human ST2 (cat # DY523), human 
trappin-2/elafin (cat # DY1747), and human HGF (cat # DY294) were purchased from R&D 
Systems and SuperSignal ELISA Femto Substrate (cat # 37074) was purchased from Thermo 
Scientific. 
 
3.2.2. ELISA Protocol 
Manufacturer specifications for ELISA assays were followed, with several modifications. 
Briefly, polystyrene plates of various formats were coated with either a mixture of capture 
antibodies or separate capture antibody spots reconstituted in PBS. The plates were then wrapped 
in Parafilm to limit evaporation and stored at 4 ˚C overnight. Plates were washed five times with 
wash buffer (PBS, containing 0.05% Tween-20), and blocked with 3.0 wt% casein for 1 h.  After 





Following antigen application, plates were washed five times and incubated for 2 h with 
detection antibody in either a traditional ELISA or ATPS-ELISA format. For conventional 
multiplexed ELISAs, detection antibodies were bath applied according to manufacturer 
specifications. For ATPS-ELISAs, the plate was first filled with a solution of PBS containing 
PEG and 0.1 wt% casein. DEX droplets containing the appropriate biotinylated detection 
antibody were then pipetted into the PEG. Following detection antibody incubation, the plates 
were washed eight times followed by incubation with streptavidin-conjugated horseradish 
peroxidase for 1 h. Plates were then washed five times and incubated with SuperSignal ELISA 
Femto Maximum Sensitivity Substrate (37074, Thermo Scientific). Chemiluminescent signal 
was detected using either a ChemiDoc XRS (BioRad) or FluorChem M (Protein Simple) imaging 
system. 
 
3.2.3. Plate fabrication 
Untreated polystyrene plates were used for both ATPS-ELISAs and conventional 
multiplexed ELISAs.  To reduce the volume of sample required to perform the assay, several 
methods were used to customize the plates. In the alpha prototypes of the custom plate, sample 
volumes were contained by attaching a hydrophobic tape stencil to the plate surface. To aid in 
localization of capture antibody spots and DEX droplets containing detection antibody an 
indented array was fabricated as a feature of the plate surface by drilling into the surface of the 
polystyrene. The resulting indentations were ~2 mm in diameter and ~1-2 mm in depth. Beta 
prototypes of the custom plate were designed in AutoCAD (Autodesk) and SolidWorks (Dassault 
Systemes). Aluminum molds, containing a 9x9 array of 6.5 mm diameter sample wells that each 





micromachining (Protomatic, Inc., Dexter, MI). Polystyrene dishes were heated above their glass 
transition temperature and the aluminum mold was stamped into the dish to mold the plate to its 
final dimensions.  
 
3.2.4. Plasma samples 
Heparinized plasma samples were collected from patients who received allogeneic bone marrow 
transplantation at the University of Michigan between 2000 and 2010. Plasma samples were 
collected under protocols approved by the University of Michigan Institutional Review Board 
and stored at the University of Michigan. To mitigate effects associated with mismatch between 
the standard diluent and plasma sample several approaches were taken.  First, an appropriate 
dilution of plasma was determined for each biomarker.  Next, spike and recovery and linearity of 
dilution for the standard and sample diluents containing FBS, BSA and/or healthy pooled plasma 
were investigated. Finally, a standard diluent of 10% healthy pooled plasma and 1% FBS, and a 
sample diluent of 10% patient plasma and 1% FBS were selected and used for all patient sample 
analyses. 
 
3.2.5. Statistical analysis 
All plots and statistical analyses were carried out in either Sigmaplot with Sigmastat (Systat 
Software) or Graphpad.  Standard curves were fitted using a four parameter logistic function that 
was used to predict unknowns. The limit of detection (LoD) was determined from the equation 
LoD = LoB + 1.645 (SDlow concentration sample), where SD is the standard deviation and LoB is the 





2008). Linear dynamic range (LDR) was determined using LDR = Maximum linear response/ 
LoD.  To compare ATPS-ELISA values with conventional ELISA values, a Pearson product-
moment correlation test was used with values of |0.3-0.5| and |0.5-1.0| considered to be medium 
strength and strong correlations respectively. 
 
3.3 Results and Discussion 
3.3.1. Optimizing ATPS parameters for multiplexed ELISAs 
ATPS-ELISA (Fig. 3.1A) is performed using similar steps to conventional sandwich ELISA 
(Fig. 3.1B). The main difference is that ATPS-ELISAs use detection antibody solutions that are 
deposited in DEX droplets over pre-arrayed capture antibody spots. Localization of detection 
antibodies in dextran droplets prevents antibody cross-reactions because interaction of multiple 
detection antibodies as well as non-target antigen recognition by detection antibodies is hindered.  
 We studied the effect of chemiluminescent ELISA signal as a function of polymer 
concentrations (Fig. 3.2A-B). We observed that signal area decreased as polymer concentration 
increased for each phase system tested. This is in part due to the increased interfacial tension and 
viscosity at higher polymer concentrations, which prevent dextran droplets from spreading. To 
demonstrate that detection antibodies are retained within the DEX phase during ATPS-ELISAs, 
we performed time-lapse studies of phycoerythrin (PE)-IgG in DEX over the course of 2 h (Fig. 
3.1C). DEX-confinement of the fluorescent detection antibodies over this time period indicated 
that detection antibodies partitioned stably in the DEX phase. We selected the 20% DEX 
500K/20% PEG 35K system for multiplexed ELISAs because this ATPS produced the smallest 






3.3.2. ATPS is necessary to prevent antibody cross-reactions 
 To confirm that an ATPS was required to localize the antibodies, we spotted the detection 
antibody on a dry well that had been treated with capture antibody and antigen (Fig. 3.3A). The 
detection antibody spread across the well, producing a large signal area that would prevent 
multiplexing. In contrast, in ATPS, a pronounced discrete chemiluminescence signal was 
observed (Fig. 3.3B).  Finally, if the detection antibody was introduced into a PEG bath with a 
PBS carrier solution, the detection antibody could not come into contact with the plate and no 
signal was observed (Fig. 3.3C). These experiments demonstrate that a PEG/DEX system is 
absolutely necessary for localizing detection antibodies in our multiplexed ELISA format. 
Next, we systematically proved that ATPSs prevented detection antibody crosstalk (Fig. 
3.4). First, we deposited closely spaced droplets of capture antibodies: a mouse anti-human 
antibody recognizing tumor necrosis factor receptor (TNFR1) and an anti-goat antibody 
recognizing the goat anti-human TNFR1 detection antibody. After incubating with a solution 
containing TNFR1, the goat detection antibody was spotted above the mouse capture antibody-
antigen complex in DEX. Upon analysis it was clear that there was no cross-reactivity signal for 
the ATPS format (Fig. 3.4A), while significant cross-reactivity was observed during 
conventional bath application of the detection antibodies (Fig. 3.4B). We next performed a 
duplex experiment with capture and detection antibodies for TNFR1 and ST2, where both the 
capture and detection antibodies were spotted in ATPS. We observed differential signal intensity 
between the two spots, again demonstrating that crosstalk did not occur (Fig. 3.4C). When the 
detection antibodies were bath applied in the same solution, this differential signal intensity was 





Finally, we produced partial overlap of the capture and detection antibodies (Fig. 3.4E). We 
observed a “cat eye”-shaped signal area, which is only possible if the detection antibody is 
perfectly retained in the DEX droplet, again demonstrating that our system can prevent crosstalk. 
A circular spot was observed when the detection antibody was bath applied, demonstrating that 
the “cat eye” was not an artifact of poor capture antibody spotting (Fig. 3.4F). 
 
3.3.3. ATPS-multiplexed ELISAs can detect chemokines and cytokines in human plasma 
In custom plates (Fig 3.5A), we generated standard curves for four GVHD biomarkers (HGF, 
Elafin, ST2 and TNFR1) in multiplexed format either with ATPS detection antibody spotting 
(solid lines in Fig. 3.5C-F) or in indivual singleplex ELISAs (dashed lines in Fig. 3.5C-F). With 
ATPS, we obtained linear dynamic ranges (LDR: HGF, 2.0; Elafin, 0.8; ST2, 2.0; and TNFR1, 
1.6) and limits of detection (LoD: HGF, 96 pg/ml; Elafin, 1,437 pg/ml; ST2, 103 pg/ml; and 
TNFR1, 87 pg/ml) that were acceptable for prediction of GVHD in patient plasma. Multiplex 
ATPS-ELISAs generally out-performed singleplex ELISAs in terms of LDR (HGF, 1.7; Elafin, 
0.1; ST2, 1.4; and TNFR1, 2.2 for singleplex ELISA) and LOD (LoD: HGF, 124 pg/ml; Elafin, 
2,298 pg/ml; ST2, 431 pg/ml; and TNFR1, 62 pg/ml; values for singleplex ELISA). These 
observations are consistent with the observations of others and suggest that small spot sizes and 
assay volumes produce superior LoD and LDR values (Kai 2012). 
We have demonstrated a 4-plex immunoassay against biomarkers of acute graft-versus-
host-disease (GVHD) and performed tests on plasma of cancer survivors with and without 
GVHD. We compared three groups: healthy donors (n=20), allogeneic bone marrow transplant 
patients who did not get GVHD (GVHD-; n=19, median 28 days post-transplant) and allogeneic 





median 100 days post-transplant). As expected, we measured significantly higher levels of HGF, 
Elafin, ST2, and TNFR1 in GVHD+ patients as compared to healthy donors and GVHD- patients 
(Fig. 3.6A-D). We compared our multiplexed values with single biomarker ELISA values and 
observed identical trends in the mean concentration of biomarkers between GVHD and non-
GVHD patients (Fig. 3.7A-D). Notably, single biomarker ELISAs were performed in 384-well 
plates instead of 96-well plates, not only to conserve patient plasma but also because the signal 
spot size between 384-well single ELISAs was comparable to our ATPS-AlphaLISA. ATPS-
ELISA chemiluminescence values correlated well with individual sandwich ELISAs by Pearson 
product-moment correlation (ρ=0.86, 0.72, 0.71, and 0.68), providing evidence that our ATPS-
ELISA system is in accordance with conventional ELISA (Fig. 3.8A-D). Receiver operating 
characteristic (ROC) analysis indicated that our test was sensitive and specific for all four 
biomarkers, as determined by measuring the area under the curve (Fig. 3.9A-B). We postulate 
that the ATPS-ELISAs generally had better ROC curves than single biomarker ELISAs because: 
(i) washing small 384-wells for single ELISAs was difficult and poor washing may have resulted 
in higher background signals, (ii) we observed some optical crosstalk in signals obtained in 
standard ELISAs, which could also have increased our background signals, and (iii) difficulty in 
pipetting into small 384 wells may have resulted in uneven distribution of the chemiluminescent 
substrate in assay wells and also result in large signal variability. Collectively, these results 
indicate that the multiplexed ATPS-ELISA system can be used to detect complex diseases, such 
as acute GVHD, by simultaneously measuring the levels of multiple plasma biomarkers. 
We developed a method that enables crosstalk-free multiplexing of commercially 
available ELISA kits. Confinement of detection antibodies in ATPS droplets effectively prevents 





biomarkers in recipients of allogeneic bone marrow transplants. Our results demonstrate that the 
ATPS-ELISA system can discriminate between acute GVHD patients and healthy transplant 
recipients with a low rate of false-positives, suggesting that this will be a clinically useful tool 
for GVHD diagnosis. Our assay offers several advantages over conventional singleplex ELISAs 
including use of small plasma volumes (10 µl of diluted plasma for four biomarkers), one 
hundred-fold less detection antibody consumption, and most importantly complete lack of 
antibody crosstalk in the multiplexed format. Other potential benefits that enhance the 
multiplexed ATPS-ELISAs include microscale surface localization effects that enhance detection 
antibody binding, more effective washing due to the shallow well profiles, and less depletion of 
chemiluminescent substrate, all of which can affect LoD and LDR.  
 
3.4 Conclusions 
In summary, we engineered a unique crosstalk-free multiplexed ELISA platform that prevents 
antibody crosstalk and produces high quality data with sensitivity similar to or better than 
existing singleplex ELISAs. Fewer wash steps minimize user error and allow faster time-to-first 
results. No specialized readers are needed, allowing substantial cost savings to researchers 
(chemiluminescent-based imagers or even light sensitive film can be used for readouts). Most 
importantly, the microscale patterning technology allows robust multiplexing of any ELISA that 
can be reliably performed in singleplex format.  There is no need to cross-validate reagents every 






Figure 3.1: Schematic of (A) conventional multiplex ELISA and (B) multiplex ATPS-ELISAs. 
(C) Time-lapse fluorescent images, showing detection antibodies partition stably in dextran 







Figure 3.2: Effect of polymer concentrations and polymer molecular weights on signal area of 
chemiluminescent ELISA signals. Multiplex ATPS assays were blocked with either (A) casein or 
(B) bovine serum albumin (BSA).  
 
Figure 3.3: ATPS is necessary for localized chemiluminescent signals in multiplex ATPS- 
ELISAs. (A) In dry wells, without ATPS, signal spreads throughout well of 96-well plate. (B) In 
PEG/DEX ATPS, the chemiluminscent signal is localized. (C) In PEG only, no chemiluminscent 






Figure 3.4: Localized ATPS-ELISA detection antibody patterning eliminates antibody cross-
reactions (A, C, E) while bath application of detection antibody in conventional multiplexed 







Figure 3.5: Multiplexed ATPS-ELISA for GVHD biomarkers. (A) Three-dimensional image 
showing custom plate design consisting of 4 DEX/antibody insets within a common shallow 
sample well. (B) Representative images of chemiluminescent standards. (C-E) Standard curves 
for all four GVHD biomarkers in PBS generated by densitometric quantification of 
chemiluminescence images compared to individual sandwich ELISAs (dashed lines).  Error bars 








Figure 3.6: Multiplexed ATPS-ELISA detection of (A) HGF, (B) Elafin, (C) ST2, and (D) 
TNFR1 in plasma from patients who underwent bone marrow transplantation. The GVHD+ 
group displayed significantly high levels of all four biomarkers compared to the GVHD – and 
healthy control groups (p<0.05 by one-way ANOVA with Dunn’s multiple comparison test). 







Figure 3.7: Measurement of (A) HGF, (B) Elafin, (C) ST2, and (D) TNFR1 from patient plasma 
using individual sandwich ELISAs.  Significance between the GVHD+ group and the GVHD- 
and healthy control groups was obtained for HGF and TNFR1 (p<0.05 by one-way ANOVA 
with Dunn’s multiple comparison test), but not for elafin or ST2, although ST2 values for the 








Figure 3.8: Scatter plots showing correlation between patient sample measurements for ATPS-
ELISA (x-axis) and single sandwich ELISAs (y-axis) for (A) HGF, (B) Elafin, (C) ST2, and (D) 






Figure 3.9: Receiver operating characteristic (ROC) curves for multiplexed ATPS-ELISA (A, 
solid lines) demonstrate that the assay has high sensitivity and specificity for determining GVHD 
status from biomarker levels in patient plasma.  Single sandwich ELISAs (B, dashed lines) were 
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Conclusions and Future Directions 
4.1 Summary 
Many multiplex protein biomarker tests exist but these tests (i) are time- and labor-intensive to 
develop, (ii) have poor specificity due to antibody cross-reactions, (iii) have high sample and 
reagent consumption, and (iv) require expensive, specialized equipment (ELISA Trends 2010). 
The innovative, crosstalk-free, homogeneous and heterogeneous, multiplexed immunoassays 
developed in this dissertation research successfully solve all four challenges faced by these 
commercially available platforms.  
In fact, we enabled, for the first time, multiplexing of amplified luminescent proximity 
homogeneous assays (AlphaLISAs) by co-localizing antibody-bead reagents in droplets of 
immiscible aqueous polymers (Chapter 2). It is this microscale reagent patterning technique that 
allows our no-wash, multiplexed assay to also prevent the antibody cross-reactivity problem that 
plagues many current multiplexed protein assays. In previous methods, these antibody cross-
reactions result in false positive detection, reducing test specificity. Not only is our assay highly 
specific and highly sensitive, with a wide dynamic range of 3.5 log units, but it is also 
inexpensive because we use tenfold less antibody-bead reagents than standard AlphaLISAs. In 
addition, our assay can be completed in 2 hours and can be read using standard 384-well 
microplate readers. We demonstrated the potential of C-X-C motif chemokine 9 (CXCL9) and 





disease by quantifying these proinflammatory chemokines in plasma from 88 patients who 
underwent bone marrow transplantation. In addition, we quantified the levels of IL-6, IL-8, 
CXCL9 and CXCL10 in antigen-stimulated cell cultures of human pulmonary type II alveolar 
epithelial cells. These experiments indicated that our assay is a valuable alternative detection 
method to AlphaLISA and enzyme-linked immunosorbent assay (ELISA) for protein 
quantification in cell culture supernatant and human plasma.  
Similarly, our heterogeneous, crosstalk-free, multiplex ELISA is one of only two ELISA-
based technologies that prevent antibody cross-reactions, ensuring that life scientists can detect 
proteins more accurately in biological samples. In conventional multiplex ELISAs, a cocktail of 
detection antibodies is introduced into assay wells, and these antibodies bind nonspecifically to 
each other leading to antibody crosstalk. In contrast, in multiplex ATPS-ELISAs described in 
Chapter 3, detection antibodies are localized within spatially, discrete dextran droplets. Thus, 
each detection antibody is matched only with its corresponding pre-spotted capture antibody. 
The other ELISA-based technology that claims to prevent antibody crosstalk is called the 
antibody co-localization array; however, these arrays are disadvantageous because droplets of 
detection antibody solutions are printed in dry environments and so may easily evaporate before 
test completion (Pla-Roca et al. 2012). Instead in ATPS-ELISAs, detection antibody solutions 
are printed in hydrated ATPS environments; hence, there is no risk of evaporation. Like our 
ATPS-AlphaLISAs, the ATPS-ELISAs use less sample and less antibodies than conventional 
immunoassays. Specifically, ATPS-ELISAs only requires 1 µl neat plasma, which is 50 times 
less the sample volume used in standard ELISAs. This savings in sample consumption is 
particularly advantageous in pediatric testing when patient sample size is small to begin with. 





huge cost savings to researchers. 
We expect that both crosstalk-free multiplex immunoassay platforms will revolutionize 
the life science research and clinical diagnostics markets because these platforms are the only 
current technologies that eradicate antibody cross-reactions in multiplex protein tests. By 
preventing antibody crosstalk, our assays do not detect false positive signals and so enable more 
accurate protein biomarker detection and diagnoses. Currently the research market is crowded 
with key players, namely RayBiotech Inc., Luminex, Quansys, and Meso Scale Discovery 
(MSD), who were all interviewed in the 2012 National Science Foundation Innovation-Corps 
Program. However, none of their multiplexed assays can be completed without wash steps or/and 
without antibody crosstalk (Table 4.1).  
         Table 4.1: Comparison of ATPS-multiplexed assays to commercial multiplexed assays. 
 
There are many emerging technologies that are entering in the multiplexed immunoassay 
space. For example, single molecule arrays (Simoas), sold by Quanterix Corporation, boast of 
femtomolar detection limits. In Simoas, analytes in the sample fluid are concentrated into very 
small chambers such that the concentration of analyte molecules in the chambers is greater than 
the bulk sample solution. This concentration-by-microcompartmentalization technique explains 





suffer from antibody crosstalk due to use of detection antibody cocktails; hence, the technology 
can only multiplex up to 10-plex.  
Given the significant across-the-board cuts per the recent government sequestration, 
researchers are receiving less federal funding. Less research funding drives researchers to seek 
inexpensive, alternative technologies. Since our ATPS-multiplexed assays reduce antibody costs 
by 10- to 100-fold, we expect that life science researchers will be incentivized to adopt these 
technologies. Furthermore, no specialized readers are needed, allowing substantial cost savings 
to researchers. Instead, common lab instruments such as digital chemiluminescent-based imagers 
(Western blot readers) and 384-well microplate readers can be used.  
 
4.2 Future Directions 
While this dissertation research has been instrumental in the development and validation of 
crosstalk-free multiplexed immunoassays, additional experiments can be performed to 
demonstrate the broad applicability of these assays. In particular, future directions can be aimed 
at (i) detecting biomarkers in various sample matrices, (ii) increasing assay plexing level, (iii) 
increasing dynamic range, and (iv) making assays user-friendlier.  
 
4.2.1. Detecting biomarkers in additional sample matrices 
In this work, biomarkers quantified by both ATPS-multiplexed assay platforms were limited to 
two sample matrices: cell culture supernatants and human plasma. However, other biological 
fluids like serum, cell lysates, broncho-alveolar lavage fluid (BALF), and urine are often used to 





that our ATPS-multiplexed assays are robust enough to enable reliable and accurate biomarker 
quantification in all other sample matrices.  
 
4.2.2. Increasing assay plexing level 
To date, we have successfully developed 4-plex ATPS-AlphaLISAs and 4-plex ATPS-ELISAs. 
Typically, multiplex immunoassays that allow simultaneous detection of less than 10 biomarkers 
are beneficial for disease diagnosis, in part, because the algorithm used to diagnose patients can 
be made simple (Brand et al. 2011; Daly et al. 2013). Assays that enable multiplexed detection 
of more than 10 biomarkers are used for biomarker discovery and studying signal transduction 
pathways. Mass spectrometry, for example, is used extensively in biomarker discovery because it 
provides high throughput multi-analyte analysis. The drawbacks are mass spectrometry is very 
expensive and it is not sensitive enough to detect low abundance biomarkers (detection limit, 2 
µg/ml) (Addona 2009). Luminex platforms are also used for biomarker discovery and a custom 
50-plex cytokine panel is offered by Stanford’s Human Immune Monitoring Center. Since our 
crosstalk-free multiplex assays are inexpensive compared to both Luminex and mass 
spectrometry, and have greater sensitivies than mass spectrometry, developing 16- or 100-plex 
ATPS-AlphaLISAs or ATPS-ELISAs will be extremely advantageous. In the current format, 
ATPS-AlphaLISAs may be limited to 16-plex because most plate readers are constrained to 
reading 1536-well plates. ATPS-ELISAs, however, can theoretically detect 100-plex and higher 
because chemiluminescent detection is obtained via digital imagers. In addition, since both 
ATPS-AlphaLISAs and ATPS-ELISAs inherently prevent antibody crosstalk, any singleplex 
AlphaLISA or ELISA can be added into the respective ATPS-multiplexed format without 






4.2.3. Increasing assay dynamic range 
Methods to increase the dynamic range of our crosstalk-free multiplexed assays can also be 
explored. Biomarkers in the blood span a concentration range of 11 orders of magnitude. 
Therefore, some biomarkers may be present in pg/ml concentrations while others may be present 
in µg/ml or mg/ml concentrations (Anderson and Anderson 2002). To increase the dynamic 
range of ATPS-AlphaLISAs, the following parameters can be optimized for each measured 
biomarker: antibody concentrations, antibody affinity, and charge of dextran. Increasing acceptor 
bead concentrations means there are more capture antibodies per bead, ensuring maximal capture 
of target biomarkers. However, since acceptor beads elicit the chemiluminescent signal, 
increasing acceptor bead concentrations result in higher background levels. An optimum 
acceptor bead concentration is therefore crucial. Use of high affinity antibodies also ensures that 
maximal target biomarkers are sandwiched between acceptor beads and biotinylated antibodies. 
Although we may carefully design assays so that antibodies and acceptor beads partition strongly 
to dextran assay droplets, if antibodies have low affinities for the target biomarker, detection 
limits will be higher and dynamic range will be reduced. It is well known that partitioning of 
proteins in an ATPS is dependent on the ionic composition of the phase-forming polymers 
(Albertson 1986). Thus, the influence of individual dextran-charged droplets, pH adjustments, or 
salt additions can be studied to determine the condition for best biomarker partitioning.  
Optimum biomarker partitioning leads to increased biomarker captured by antibody-beads, 
increasing dynamic ranges. 
For ATPS-ELISAs, use of high affinity antibodies as well as optimum antibody 





disadvantage of our chemiluminescent ATPS-ELISAs is the inability to manipulate the exposure 
per measured biomarker. Some biomarkers give strong signals and some give weak signals at the 
same exposure. Consequently, it is difficult to discriminate between weak signals, reducing assay 
dynamic range. To overcome this, ATPS-ELISAs can be adapted into a fluorescent readout by 
use of multi-color Cy3/Cy5/FITC-conjugated detection antibodies. In this fluorescent format, it 
will be relatively easy to adjust the exposure of each measured biomarker because a different 
labeled detection antibody will detect each biomarker. This should increase the dynamic range of 
ATPS-ELISAs. 
 
4.2.3. Improve assay’s ease-of-use: rehydratable antibody microarrays 
Efforts can also be pursued to make assays user-friendlier or/and automated. Since custom 
microplates for the multiplexed ATPS-AlphaLISAs satisfy the Society of Biomolecular 
Screening standards for 384-microwell plates, liquid handlers (e.g., CyBi®-Well, CyBio, Inc.) 
can be used to automatically dispense dextran/donor beads during the second step of our assay. It 
may also be possible to reduce the number of pipetting steps in multiplexed AlphaLISAs by 
creating rehydratable antibody microarrays (Fig. 4.1). 
In this format, antibody-conjugated beads are co-localized in dextran droplets, then dried 
by evaporation or lyophilization. When the sample solutions (mixed with PEG) are bath applied 
to the dried droplets, the dextran droplets rehydrate and enable no-wash, multiplexed detection of 
cytokines and chemokines. This potential rehydratable assay format is indeed simpler and 
positions our multiplexed ATPS-AlphaLISA to be more readily adopted by lab technicians. The 
rehydration of DEX droplets in PEG is illustrated in Fig. 4.2. We have, in fact, recently 





ATPS-AlphaLISAs. Differences in detection limits for assays with normal hydrated (wet), 
evaporated (dehydrated), and freeze-dried (lyophilized) formats are statistically insignificant, 
indicating the feasibility of this approach (Fig. 4.3A-B). For dehydrated assays, DEX droplets 
were evaporated at room temperature for 2 hours, then stored overnight at 4 °C. For lyophilized-
reagent assays, DEX droplets contained 5% D-sorbitol (Sigma), and were stored at -80 deg C for 
at least 2 to 3 hours prior to lyophilizing overnight. It is well known that polymers (e.g., dextran) 
and sugars (e.g., sorbitol) are used to stabilize proteins during freeze-drying and freeze-thawing 
(Wang 2000; Sun and Davidson 2001; Lovgren et al. 1996; Koskinen et al. 2005). On the 
following day, PEG-sample mixtures were bath applied to the dehydrated or lyophilized DEX 
droplets, and droplets rehydrated as shown in Fig. 4.2. Since singleplex rehdyratable ATPS-
AlphaLISAs can be performed, we expect that multiplex rehdyratable ATPS-AlphaLISAs are 
also feasible. 
Notably, the described rehydratable assays still require individual additions of 1-
microliter dextran/donor beads into each of the 4 microbasins within a sample well of custom 
microwell plates. We determined that all antibody-bead reagents could not be present initially in 
DEX. If strepatividin donor beads are added directly to biotinylated detection antibodies in DEX, 
large antibody-bead complexes form because of the strong binding between streptavidin and 
biotin (McMullen and Banaszak-Holl 2011). We postulate that these large complexes block 
antigen-binding sites and prevent antigens from sandwiching between antibodies and acceptor 
beads. Based on manufacturer’s specifications of antibody-bead reagents: (i) each biotinylated 
detection antibody has between 4-13 biotin molecules, (ii) each donor bead has 1000 streptavidin 
molecules, (iii) each streptavidin molecule has 3 biotin-binding sites instead of the typical 4 





molecules. Clearly, one-step rehydratable ATPS-AlphaLISAs that contain all antibody-bead 
components initially in DEX, is only possible if detection antibodies are made with only one 
biotin molecule. This will ensure that each detection antibody can only bind to one streptavidin 
molecule on the donor beads, limiting formation of complex antibody-bead aggregates. 
Instead of individual additions of 1-microliter dextran/donor beads into each of the 4 
microbasins within a sample well, with some optimization, it may be possible to just add a single 
aliquot of donor beads in assay buffer to the sample well (Fig. 4.4A). If the latter is possible, the 
end-user only has 2 manual pipetting steps per sample well, or 2 automated pipetting steps per 
plate: bath application of sample in PEG, then single aliquot addition of donor beads in buffer. 
Alternatively, it may be possible to lyophilize the bulk PEG phase as well as dextran/antibody 
droplets (Fig. 4.4B). Consequently, end-users only need to add the sample. Both the PEG and 
DEX phases will rehydrate, and antigens in the sample should easily diffuse into the DEX phase.  
ATPS-multiplexed ELISAs can also be made user-friendlier if both capture and detection 
antibodies are first pre-spotted and dried onto custom well plates. Antigen samples would be 
bath applied in PEG to dehydrated DEX-immobilized antibodies. DEX antibodies would then 
rehydrate upon addition of PEG. This format is advantageous to the end-user because not only 
does it eliminate user addition of capture and detection antibody solutions, but it also eliminates 
some washing steps. Consequently, the total assay time will reduce. In the proposed format, 
precise layered printing of capture and detection antibodies is absolutely necessary. This format 
is very challenging because it requires the printing of DEX layers in such a way that does not 
cause mixing prior to rehydration with PEG. Each time an additional DEX layer is spotted on an 
existing layer, there is a possibility of partial rehydration of the underlying DEX layer. Partial 





causing multiple rounds of evaporative drying, denaturing proteins in solution. If, however, this 
challenge can be overcome, then this assay format will be extremely beneficial to translational 
researchers. 
 
4.2.4. Commercialization potential 
We participated in the 2012 National Science Foundation Innovation-Corps (NSF I-Corps), a 
fast-paced set of programs that allow researchers to evaluate the commercialization potential for 
their technology. We interviewed nearly 100 potential customers in hospitals, diagnostic labs, 
research labs, contract research organizations, and pharmaceutical companies. Clinicians 
expressed sincere interest in using our crosstalk-free multiplexed assays as a point-of-care 
device, particularly for the diagnosis of neonatal sepsis. Currently clinicians use 3 – 5 ml sample 
volumes for their studies, so a test that only requires a few microliters of blood is a major 
advancement. Before a point-of-care assay can be developed for sepsis, two major improvements 
to our ATPS-AlphaLISAs must be completed: 1) use of whole blood instead of blood plasma, 
and 2) 20 to 30 minute total assay time instead of 2 hours.  
Translational researchers in academic institutions also value the rapid customizability of 
our crosstalk-free multiplexed platforms. No systematic analysis of all possible nonspecific 
interactions is necessary to develop and validate new biomarker panels because of the inherent 
ability of our assay to prevent antibody cross-reactions. Therefore, any singleplex ELISA or 
AlphaLISA can be included in our ATPS-multiplexed assays. No commercial technologies can 
customize and validate assays so rapidly. In fact, some multiplexed immunoassay companies 
charge as much as $20,000/protein added to in the multiplex test. This means that a custom 4-





by eliminating the need for lengthy optimizations of reagent and assay conditions, our custom 
crosstalk-free assays can potentially be developed in one-tenth the time. Furthermore, being the 
first-to-publish drives academics, so waiting 12 months for a custom assay may make researchers 
lose their window of opportunity. In addition, researchers cannot afford these high costs for 
custom assay development. Our ATPS-multiplexed assays are beneficial to researchers because 
reagent costs are reduced by 10- to 100-fold. 
Life scientists at pharmaceutical companies also value our highly customizable, 
crosstalk-free multiplexed assays. Rapidly developed custom biomarker assays that prove or 
disprove drug efficacy is extremely valuable to pharmaceutical companies. Eliminating 



















Figure 4.2: Schematic of workflow for rehydratable multiplexed ATPS-ALphaLISAs. (A) DEX 
droplets (1 µl), containin co-localized antibody-bead reagents, are air-dried or freeze-dried. (B) 
PEG-sample mixture is bath applied. (C) During a 1-hour incubation, antigens diffuse from PEG 
into the DEX droplets, and bind to antibody-beads. (D) DEX droplets (1 µl), containing 
streptavidin-coated donor beads are introduced into the solution and incubated for another hour. 
Donor beads bind to biotinylated antibodies, eliciting amplified luminescent signals by acceptor 





Figure 4.3: Rehydratable singleplex IL-6 ATPS-AlphaLISA. (A) Standard curves comparing 
wet, dehydrated, and lyophilized DEX assays. (B) Limit of detection of IL-6 in wet, dehydrated, 






Figure 4.4: Two methods to reduce pipetting steps in ATPS-multiplexed AlphaLISAs: (A) 
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This section describes the utility of phase-forming polymers for localized induction of apoptosis 






Aqueous Two-Phase System Patterning of Microbubbles: Localized Induction 
of Apoptosis in Sonoporated Cells 
 
This chapter describes an innovative high throughput method to study cell apoptosis. In this 
method, gas-filled microbbubbles were localized within microliter droplets of immiscible 
polymer solutions. Typically, these microbubbles float in aqueous environments so antibody-
conjugated microbubbles are needed to anchor microbubbles to cell membranes. In our study, by 
simply confining these microbubbles in dextran droplets, microbubbles were maintained in close 
proximity to cell membranes. When ultrasound was applied, pores were generated in cell 
membranes, causing calcium influx into the cells and subsequently induce cell apoptosis. The 
simplicity of patterning microbubbles in dextran droplets over cell monolayers enables the highly 












Microscale patterning is used extensively in tissue engineering and biomedical engineering for 
high-throughput cell assays and investigation of interactions among cell populations. Patterning 
is typically achieved by depositing materials on a substrate prior to cell attachment (e.g., 
microcontact printing, stenciling and inkjet printing) or by localizing reagents over a preexisting 
cell monolayer (e.g., laminar flow patterning or microelectromechanical system (MEMS)- based 
culture platforms) (Hook et al. 2006, Takayama et al. 2001, Takayama et al. 2003, Jain and 
Muthuswamy 2007, Valley et al. 2009). However, these strategies can be difficult to translate to 
widespread use in the life sciences because they often use custom fabricated devices that require 
a high degree of user expertise to operate. 
To overcome these limitations, we recently developed a user-friendly, non-contact, cell-
compatible method to pattern cells and deliver biomolecules to discrete cell populations. This 
method involves the localization of biomolecules within the dextran phase (DEX) of a 
polyethylene glycol (PEG)/DEX aqueous two-phase system (ATPS) (Tavana et al. 2010, Tavana 
et al. 2010, Yaguchi et al. 2012). Here, we use an ATPS to pattern lipid-coated, gas-filled 
microbubbles to discrete regions on a cell monolayer, where they can be excited by ultrasound 
and induce localized cell apoptosis. 
It is well known that after ultrasound application, microbubbles rapidly expand and 
contract, and/or collapse, and disrupt cell membranes (Marmottant and Hilgenfeldt 2003, 
Postema et al. 2004, Prentice et al. 2005, Ohl et al. 2006, van Wamel et al. 2006). The 
membrane disruption mediated by ultrasound excitation of microbubbles, referred to as 
sonoporation, has found applications both in vitro and in vivo, emerging as a valuable, 





impermeable exogenous agents into cells or to induce cell death (Ohl et al. 2006, Miller et al. 
2002, Kudo et al. 2009). However, sonoporation is limited by a lack of control over microbubble 
location with respect to cells, often resulting in variable treatment outcomes and suboptimal 
efficiencies. Gas-filled microbubbles easily float to the surface of the cell culture medium in 
vitro, far from where they can exert their effects on adherent cells.  
To circumvent the microbubble buoyancy problem, microbubbles are encapsulated with 
antibodies/ligands that target them to the surface of cells (Ferrara et al. 2009, Klibanov 2009, 
Linder 2004). These targeted microbubbles attach to cell membranes, and facilitate membrane 
disruption (Warram et al. 2012). Application of antibody-conjugated microbubbles to in vitro 
cell monolayers, however, results in microbubbles binding to the entire monolayer. Such systems 
do not provide the spatial selection that is required to target subpopulations of cells within a 
monolayer. Furthermore, expensive antibodies/ligands are needed to attach the microbubbles to 
the cells. 
In this study, we address these limitations by spatially patterning microbubbles (without 
expensive antibodies) using ATPSs, and confining them to user-defined regions on a cell 
monolayer. Application of ultrasound results in localized sonoporation in patterned microbubble 
regions. This localized sonoporation cannot be achieved by any current methods. Moreover, the 
patterned microbubbles allow both the experimental treatments and the control (where cells 
within different regions are exposed to the same ultrasound condition without microbubbles 
nearby) to be simultaneously performed, in one step, in a single cell culture dish. By patterning 
microbubbles at multiple sites, multiple ultrasound conditions can be tested within the same 
culture dish, providing a multiplexed platform for efficient investigation of ultrasound-mediated 





5.2 Materials and Methods 
5.2.1 ATPS Formulation 
ATPSs were formulated from DEX (ranging in molecular weight from 3.5 kDa to 500 kDa; 
Pharmacosmos, Denmark) and PEG 35 kDa (Sigma, St. Louis, MO). These polymers were 
reconstituted as aqueous solutions in various buffered media. The initial formulations tested were 
near critical point concentrations of 9% DEX 3.5 kDa/10% PEG 35 kDa, 7% DEX 10 kDa/7% 
PEG 35 kDa, and 3.2% DEX 500 kDa/2.5% PEG 35 kDa in their fully equilibrated forms. For 
experiments that required additional reagents in the ATPS solutions, concentrations slightly 
higher than the critical points were used (e.g., stock solutions of 16% DEX 10 kDa/16% PEG 35 
kDa, corresponding to a solution of approximately 8% DEX 10 kDa/8% PEG 35 kDa after full 
equilibration. ATPSs formed from stock solutions of 8% DEX 10 kDa/16% PEG 35 kDa and 4% 
DEX 10 kDa/16% PEG 35 kDa were also tested. 
 
5.2.2 Microbubble Partitioning 
Two types of commercially available ultrasound contrast agent microbubbles were used in this 
study: Definity (Lantheus Medical Imaging, Billerca, MA) and Targestar-SA (Targeson, San 
Diego, CA). Definity microbubbles are composed of a C3F8 gas core, encapsulated by a 
phospholipid shell. Targestar-SA is a perfluorocarbon microsphere, encapsulated with a lipid 
shell coated with streptavidin, which permits biotinylated ligands to bind to its surface via biotin-
streptavidin conjugation chemistry. The affinities of different microbubbles for the above phase 
systems were tested by mixing stock solutions of microbubbles in equal concentrations of twice-





allowed to separate by gravity at room temperature. Once the phase systems reached equilibrium 
(∼10 min), samples were taken from the top (PEG) and bottom (DEX) phases along with the 
PEG/DEX interface and diluted below the critical point (1:10 in PBS) to remove any residual 
PEG/DEX droplets that could be mistaken for microbubbles. Microbubbles were placed on a 
hemocytometer and imaged under brightfield illumination using a 10x objective. Images were 
imported into imageJ and numbers of microbubbles were automatically quantified using the 
automated nuclei counting plugin (Center for Bio- Image Informatics, UCSB). Partitioning was 
measured for Definity lipid coated microbubbles, Targestar-SA microbubbles (without antibody) 
and Targestar-SA microbubbles conjugated to biotinylated IgG by counting the numbers of 
microbubbles in each phase. Partitioning was also investigated by placing the microbubbles 
within non-equilibrated twice-concentrated solutions of DEX, which were then deposited into 
PEG as 1 µl droplets. The movement of microbubbles within the DEX droplets was monitored 
using video microscopy. 
 
5.2.3 Cell Culture 
Human umbilical vein endothelial cell (HUVEC) preparations (passage number 3-7) were plated 
one day prior to the experiment onto tissue culture treated 35 mm2 glass bottom dishes. NIH3T3, 
MDA231 and HeLa cells were cultured under standard conditions and then either seeded 
separately or as mixtures (co-cultures) in HUVEC medium in 35 mm2 glass bottom dishes one 
day prior to the experiment. A seeding density of 200 cells/mm2 was used to ensure ∼80% 
confluence the following day. Cultures were maintained in a humidified incubator at 37°C, with 
5% CO2. For experimental treatments, cultures were removed from the incubator, covered with a 





After 10 min incubation, the ATPS was removed through 3-5 consecutive washes in PBS. The 
cells were then either reintroduced to culture medium and returned to standard incubation 
conditions for later analysis or immediately stained and imaged. 
 
5.2.4 Microbubble Preparation and ATPS Micropatterning 
Microbubbles (∼1 × 109 particles/ml) were incorporated into the DEX phase by mixing a solution 
of 32% DEX 10 kDa with an equal volume of microbubbles to obtain a solution of ∼0.5 × 109 
microbubbles/ml in 16% DEX, representing the optimal microbubble concentration. Solutions 
with 10-fold and 100-fold lower microbubble concentrations were also tested. The microbubble 
solutions were loaded into capillary needles that were positioned above the PEG coated cells. 
Capillary tips were lowered into the PEG and droplets of DEX containing microbubbles (∼0.05–
0.1 µl in volume) were dispensed in the desired patterns above the cells. These droplets sank 
vertically in the PEG solution, where they came into contact with the cells and spread on the cell 
monolayer. Once the final droplet was in place, the micropatterned cultures were ready for 
ultrasound exposure. 
 
5.2.5 Experimental Setup for Ultrasound Application 
The experimental setup consisted of a microscope equipped with a non-focused circular 
ultrasound transducer (center frequency 1.25 MHz, active element diameter 0.6 cm) (Advanced 
Devices, Wakefield, MA, USA) that was driven by a function generator (33250A, Agilent 
Technologies, Palo Alto, CA, USA) and an amplifier (75A250, Amplifier Research, Souderton, 





hydrophone (HPM04/1, Precision Acoustics, Dorchester, UK). The transducer was positioned at 
45 degrees (to avoid standing wave buildup and accommodate simultaneous microscopic 
imaging) with its active surface ∼7.5 mm (Rayleigh distance) from the cell culture surface such 
that the maximum ultrasonic pressure was focused on the cells. This configuration allowed us to 
simultaneously apply ultrasound and microscopically observe microbubbles. Ultrasound 
excitation of microbubbles was monitored by a high-speed camera (Photron FASTCAM SA1, 
San Diego, CA) at a frame rate of 20 000 frames per second. A cooled CCD camera 
(Photometrics QuantEM, Tucson, AZ, USA), a monochromator with 5 nm bandpass (DeltaRAM 
X, PTI, Birmingham, NJ, USA) and a polychroic filter (73000v2, Chroma, Rockingham, VT, 
USA) were used to perform ratiometric epifluorescence and standard epifluorescence imaging of 
molecules delivered by sonoporation. The ultrasound treatments were applied either as single 8 
µsec pulses or as continuous (30 s) wave forms that varied in peak acoustic pressure from 0.05 
MPa to 0.6 MPa. 
 
5.2.6 Apoptosis and Calcium Influx 
To investigate whether calcium influx during sonoporation plays a role in sonoporation-triggered 
apoptosis in our system, we used PEG solutions containing various calcium concentrations either 
in a buffer designed to mimic the intracellular ion concentration of cells (Cytomix) or in 
PBS/DPBS (van den Hoff et al. 1992). Calcium concentrations ranged from 0 to 20 mM. Cells 
were exposed to either 0.3 or 0.6 MPa peak acoustic pressures and allowed to recover for 15 min 
at room temperature before washing in PBS. Cells were then washed in annexinV binding buffer 
and incubated with a solution containing Alexa 488-annexinV (Invitrogen) and PI to detect 





total number of PI-positive and annexinV-positive cells was quantified as before for each 
condition, with the exception that PI was added after ultrasound treatment and used as a dead cell 
marker. Ratiometric imaging using Fura-2 AM (Invitrogen) was used to confirm that changes in 
intracellular calcium had occurred following ultrasound treatment. For ratiometric calcium 
imaging, cells were loaded with Fura2-AM before ultrasound by incubating the cells with Fura2-
AM and Pluronic F-127 (0.05% v/v of 10% w/v) for 60 min at 37 °C. The cells were then 
washed 3 times to remove extracellular Fura-2AM (Fan et al. 2010). To quantify intracellular 
calcium concentration following ultrasound, the ratio of signal at 340/380 nm was calculated for 
each treated cell. 
 
5.2.7 Viability Assays 
To analyze cell viability as a function of ultrasound/ calcium-induced apoptosis, we used several 
independent tests. PI staining, applied after ultrasound treatment, revealed cells that were not 
able to reseal their membranes after sonoporation, while annexinV labeling was used as an early 
stage marker for apoptosis. Phase contrast images were used to quantify the total number of cells 
in each image and the percentage of annexinV- and PI-positive cells was calculated for various 
ultrasound and calcium conditions. Phase contrast and PI images also allowed us to qualitatively 
inspect the status of cells in terms of general morphology, membrane features and nuclear 
morphology. JC1 ratiometric staining (Invitrogen) was used to confirm that mitochondrial 
membrane potential was disrupted in the apoptotic cells. Cell Event caspase stain (Invitrogen) 






5.2.8 Data Analysis 
Image J and MetaFluor Analyst (Molecular Devices, Downingtown, PA, USA) photometric 
software were used for image analysis. Mosaic and live cell images were captured, compiled and 
stitched using Zeiss Axiovision software. Statistical analyses were carried out using Sigmaplot 
with Sigmastat. All graphs are presented as mean values ± standard error of the mean. 
 
5.3 Results and Discussion 
5.3.1 Microbubble patterning 
We achieved microbubble patterning by dispensing droplets of DEX, containing microbubbles, 
through a glass capillary needle onto a cell monolayer immersed in PEG. Before dispensing the 
microbubbles, we broke the tip of the capillary to prevent clogging and shearing of the bubbles 
during the dispensing process. Use of a capillary needle instead of a micropipettor enabled us to 
dispense smaller droplets of DEX (∼0.05–0.10 µl) (Fig. 5.1A-C). Since DEX is denser than 
PEG, DEX droplets sink and deposit on the cell monolayer. Once in contact with the cell 
monolayer, DEX droplets spread over some cells and the DEX-localized microbubbles are 
brought in close proximity to the cell surface. Using this non-contact microbubble patterning 
method, multiple, discrete DEX droplets can be deposited within the same monolayer and even 
generate arbitraty patterns (Fig. 5.1G). After patterning the DEX droplets, additional PEG was 
carefully added to the dish without disturbing the patterning. Additional PEG must be added to 
ensure the active element at the tip of the ultrasound transducer (which was focused on the cells 
on the dish) was immersed. Next, ultrasound was applied to excite microbubbles and generate 





shrinking of the microbubbles near the cells (Figure 5.1D–F), confirming that the microbubbles 
in DEX behaved similarly as they do in cell culture medium (Fan et al. 2012). Ultrasound 
excitation disrupted cell membranes and induced cell death in discrete regions, as indicated by 
the staining pattern for annexinV (apoptosis) and propidium iodide (PI) (membrane disruption) 
in the microbubble-patterned regions (Figure 5.1H). 
 We observed that commercially available microbubbles patterned differently in the 
PEG/DEX system (Fig. 5.2A). Definity microbubbles partitioned primarily to the PEG and 
interface phases because the non-polar lipid shells of the Definity microbubbles were more 
compatible with PEG. Targestar-SA microbubbles partitioned primarily to the interface and DEX 
phases. A greater proportion of microbubbles were observed in the DEX phase for lower DEX 
molecular weights (3.5 and 10 kDa), most likely because proteins such as streptavidin display 
stronger partitioning to DEX at low DEX molecular weights. This was true regardless of the 
presence of conjugated antibody. Partitioning to the interface was not only dependent on 
microbubble chemistry and size, but was also caused by buoyancy of the microbubbles in DEX. 
 We confirmed microbubble partitioning by mixing microbubbles in DEX, and then 
dispensing DEX/microbubble droplets into a PEG bath (Fig. 5.2B). Definity microbubbles 
rapidly moved to the interface, with some crossing the interface and entering the PEG. In 
contrast, Targestar-SA microbubbles remained well distributed in the DEX droplet. These 
experiments allowed us to monitor the distribution of microbubbles in DEX droplets and showed 
that Targestar-SA microbubbles remained in the DEX droplets in spite of their buoyancy. 
 Next, we studied the ability of various DEX/microbubble combinations to disrupt cell 
membranes upon ultrasound application in the presence of the cell impermeable dye PI (Fig. 





droplets containing Definity microbubbles because these microbubbles rapidly escaped from the 
DEX phase and floated to the surface of the PEG, where they had no effect on the cells. 
Patterned droplets containing Targestar-SA microbubbles, however, were able to disrupt cell 
membranes allowing entry of PI into cells in the patterned microbubble regions, even without 
antibody conjugation of the microbubbles to the cells. This finding is important because it 
demonstrates the ability of micropatterned DEX droplets to spatially confine the microbubbles to 
the cell surface for sonoporation without the need for coupling to expensive antibodies. 
 For subsequent experiments we chose the DEX 10 kDa/PEG 35 kDa phase system with 
unconjugated Targestar-SA microbubbles, since this formulation displayed reasonable 
partitioning properties, and had polymer concentrations and viscosities low enough for use with 
cells. In addition, DEX 10 kDa showed more spreading on cells than DEX 500 kDa, ensuring 
that bubbles floating to the interface would still remain in close proximity to the cells. 
 
5.3.2 Effects of polymer and microbubble concentration, and cell type on cell sonoporation 
We used our DEX/microbubble patterning system to investigate cell membrane disruption and 
death as a function of ultrasound pressure, polymer concentration, microbubble concentration 
and cell type. We used PI (applied after ultrasound) as a marker for cell membrane disruption 
and cell death. Since microbubbles could be arrayed with various spacing and number of treated 
regions, this allowed us to test multiple ultrasound conditions in parallel (e.g., different numbers 
of pulses and pressure amplitudes), essentially multiplexing the ultrasound treatment (Fig. 5.3A). 
Without ATPS localization (spatial scale of ∼0.75 mm2 or less with ATPS), this type of 
multiplexing would not have been possible, since the ultrasound excitation covers a treatment 





Next, we studied the effect of DEX concentration in the 16% PEG 35 kDa/DEX 10 kDa 
system. Both the DEX and PEG used in our system are biocompatible and noncytotoxic; 
therefore, the polymers themselves had little to no direct effect on cell apoptosis. In fact, the 
intracellular cytocompatibility of these polymers has been demonstrated using lipofection as a 
membrane disruption method, as well as through numerous studies that have used cell microin- 
jection of fluorophore-conjugated polymers such as dextran for cell tracing. For these 
experiments, a single ultrasound pulse was applied (8 µs duration and 0.4 MPa peak negative 
pressure) to excite the microbubbles. A DEX concentration of 16% was optimal for maintaining 
an even distribution of microbubbles on the cells. Solutions of 8% DEX and 4% DEX produced 
clusters of microbubbles on the cells, resulting in uneven microbubble distribution, inefficient 
microbubble activation and reduced efficiency of cell membrane disruption (Fig. 5.3B). The 
clustering effect was likely due to equilibration of the DEX droplets in PEG, which caused the 
DEX solution to decrease dramatically in volume, resulting in microbubble aggregation. 
Using the 16% PEG 35 kDa/16% DEX 10 kDa system, we tested the effect of 
microbubble concentration on membrane disruption. The highest concentration of micro- 
bubbles we tested was ∼0.5 × 109/ml, which was determined by the maximum concentration of 
microbubbles provided by the manufacturer (∼1.0 × 109/ml) and the maximum concentration of 
DEX 10 kDa that could be easily prepared (32%) mixed in equal parts (0.5X microbubble con- 
dition). We also tested microbubble concentrations that were 10-fold and 100-fold lower (0.05X 
and 0.005X microbubble conditions). The efficiency of cell membrane disruption decreased 
dramatically as microbubble concentration decreased (Fig. 5.3C). 
Notably, the use of small ATPS volumes enables us to use much higher microbubble 





conditions in conventional sonoporation is, however, prohibitive because of the cost associated 
with consuming large amounts of this reagent. Although it is expected that high bubble 
concentrations should generate the strongest sonoporation effects on cells, we have observed 
interactions among microbubbles (due to the secondary radiation force or Bjerknes force) at high 
microbubble concentrations (Bjerknes 1906). This increased level of microbubble-microbubble 
interaction may influence their ability to produce direct effects on the cells during sonoporation. 
Thus, attempts to use microbubble concentrations much higher than those used in this study are 
unlikely to further enhance the efficiency of sonoporation. 
Finally, we examined the effect of cell types on membrane disruption, using the 0.5X 
microbubble condition and the 16% PEG 35 kDa/16% DEX 10 kDa system. Of the five cell 
types we tested, (HUVEC, NIH3T3, MDA 231, HeLa and HUVEC/NIH3T3/MDA231 co-
cultures), HUVECs were most sensitive to membrane disruption, but the overall level of cell 
death was similar among all other cell types (Fig. 5.3D). These results were expected because 
HUVECs, as with other types of primary cells, are typically more sensitive to physical or 
chemical disruption than immortalized cell lines and cancer cells. Cell death was less than 5% in 
control regions without microbubbles for all of the cell types we tested. Time lapse imaging of 
the ultrasound treated microbubble sites revealed that dead cells remained in place after 
treatment. Over the course of 48 h, surviving cells from the treated regions and healthy cells 
from the surrounding regions frequently interrogated the dead cells (Fig. 5.3E), eventually 






5.3.3 Platforms for Testing Cell Physiology: Apoptosis 
Most platforms for wound healing research involve either physical damage/displacement or 
chemical ablation that completely removes the cells (Liang et al. 2007, Keese et al. 2004). 
However, many types of injuries in vivo do not result in complete removal of cells from the 
tissue all at once. Rather, cells undergo a more complex removal process where they die from 
direct trauma (necrosis) or initiate their own death in response to unfavorable environmental 
factors (apoptosis) and must then be cleared by immune cells in the surrounding tissue. Thus, a 
physiological model for tissue damage should involve both necrotic and apoptotic modes of cell 
death, where the damaged/dying cells remain in place throughout the process. As demonstrated 
by the results presented in Fig. 5.3E, ultrasound excitation of patterned microbubbles can 
effectively generate cells death in targeted regions without removal of cells. Patterning 
microbubbles to control the location of this injury provides an ideal platform for investigating the 
physiology of the damaged cells and surrounding healthy regions.  
Therefore, we next investigated the mechanism of sonoporation induced cell death. Using 
patterned microbubbles, we induced cell death in well-defined regions of the cell culture and 
stained with annexinV (to assay the appearance of phosphatidylserine on the cell surface) and PI 
(applied after ultrasound, to indicate loss of membrane integrity) (Fig. 5.4A). The annexinV-
positive cells displayed a variety of morphologies indicative of apoptosis including changes in 
membrane appearance (roughening/ruffling), appearance of vacuoles and blebs and changes in 
nuclear morphology (Fig. 5.4A) (Fink and Cookson 2005, Ziegler and Groscurth 2004). We 
tested the effects of two ultrasound regimes on cell apoptosis in our system. The first regime 





treatment resulted in a low rate of acute apoptotic cell death, reaching a maximum of ∼20% at 
0.1 MPa as determined by PI/annexinV labeling. The second regime consisted of a high pressure, 
short (8 µs) pulse of ultrasound (Fig. 5.4C). This treatment increased apoptotic cell death to 
∼70% at 0.6 MPa. 
In contrast to other forms of apoptosis, our treated cells were immediately positive for 
both the apoptosis marker annexinV and the secondary necrosis marker PI, with both markers 
generally localized to the same cells. This staining pattern may be due to the ability of 
microbubbles to simultaneously disrupt the plasma membrane and initiate apoptosis, as early 
apoptotic cells without membrane disruption would normally exclude PI. We hypothesized that 
apoptosis was initiated by an influx of extracellular calcium through ultrasound-induced 
membrane disruptions. We tested the effects of the levels of extracellular calcium on loss of cell 
viability/apoptosis in regions exposed to ultrasound treatment (Fig. 5.5A-D). Higher acoustic 
pressure (0.6 MPa) resulted in a higher percentage of cells labeled with PI and annexinV, as 
compared to lower acoustic pressure (0.3 MPa) (Fig. 5.5A,B). This could be due to the fact that 
at higher acoustic pressures, more microbubbles were excited to initiate necrosis and apoptosis in 
more cells than at lower acoustic pressures. This is because smaller microbubbles usually require 
a higher acoustic pressure for cavitation to occur. 
The extracellular calcium concentration had an important impact on both the percentage 
of PI positive cells and the percentage of annexinV positive cells. The percentage of dead cells 
(both PI- and annexinV-labeled) was markedly higher when the extracellular calcium 
concentration was increased to more than 5 mM, indicating the existence of a threshold for 
extracellular calcium above which there is an increase in the percentage of apoptotic cells. 





percentage of PI-positive cells (∼60–65%) (Fig. 5.5A) was greater than the percentage of 
annexinV-positive cells (∼40– 45%) (Fig. 5.5B). This indicates that there is a pool of cells that 
die directly from microbubble trauma (acute cell death) without initiating apoptosis. This trend 
was also observed at lower ultrasound pressures (0.3 MPa), where the percentage of PI-positive 
cells (∼20–38%) was greater than the percentage of annexinV-positive cells (∼12%). However, at 
high enough calcium concentrations (e.g., ≥5 mM), almost all of the cells that were PI-positive 
were also annexinV-positive, suggesting either that increased extracellular calcium helped to 
reduce the number of cells with acute necrotic death, possibly by facilitating membrane repair 
for some cells, in accordance with what has been observed in other studies, or more likely, that 
elevated extracellular calcium concentration increased the number of cells undergoing apoptosis 
(Zhou et al. 2008). This was true for both high and low pressure ultrasound conditions. Finally, 
at high calcium concentrations (≥5.0 mM), low ultrasound pressures (0.3 MPa, 8 µs) were nearly 
as effective as high ultrasound pressures (0.6 MPa, 8 µs) at killing cells. 
We performed ratiometric calcium imaging using Fura-2AM to confirm that calcium 
entered the cells as a result of micro- bubble excitation (Fig. 5.5E). In the presence of 
extracellular calcium, there was a dramatic increase in the 340/380 nm ratio (corresponding to 
intracellular calcium concentration) that was observed immediately after the onset of ultrasound 
applica- tion, indicating that calcium was entering the cells driven by its concentration gradient. 
One consequence of rapid calcium influx is a loss of mitochondrial membrane potential, 
followed by further release of calcium from intracellular mitochondrial and endoplasmic 
reticulum stores, leading to propagation of intracellular pro-apoptotic signals (Orrenius et al. 
2003). We confirmed that this occurred in the cells within the microbubble patterned regions by 





increased level of green signal in the mitochondria indicated that mitochondrial function was 
disrupted by ultrasound induced calcium entry. Finally, to prove that cells entered the late stages 
of apoptosis, we assayed caspase activity using the Cell Event apoptosis detection kit (Fig. 
5.5G). Several hours after ultrasound treatment, almost every cell dis- played a staining pattern 
indicative of caspase activity (cleavage of the Cell Event dye which subsequently labeled the 
nucleus). These results suggest a model whereby ultrasound excitation of microbubbles in the 
presence of high extracellular calcium leads to cell death that is almost exclusively apoptotic in 
nature. Our data also suggests that apoptosis is most likely mediated by influx of calcium into the 
cells which triggers the apoptosis cascade. Cells are unable to survive as this cascade initiates, 
resulting in simultaneous loss of membrane integrity with onset of apoptosis. 
We developed a new method for patterning microbubbles for controlled ultrasound-
mediated cell membrane disruption (i.e., sonoporation). Our approach is easy to perform, can be 
applied to cells growing on a variety of substrates and offers the ability to apply multiplexed 
ultrasound/microbubble treat- ments to a small number of cells. We tested two types of 
commercially available microbubbles and found that streptavidin-coated (Targestar-SA) 
microbubbles performed better within our system. Although both Definity and Targestar-SA 
microbubbles possess a perfluorocarbon gas core bounded by a lipid shell, the difference in 
partitioning can be explained by the fact that the streptavidin on the surface of Targestar-SA 
microbubbles partitions to dextran. The ability to spatially pattern microbubbles enabled 
controlled and effective ultrasound treatment of cells. We demonstrated that patterning of micro- 
bubbles can be used to disrupt cell membranes of various cell types within defined regions, 
allowing intracellular entry of otherwise cell impermeant agents such as PI. The targeted areas 





also demonstrated that the patterned microbubbles selectively induced apoptosis in 
subpopulations of cells following ultrasound treatment. This is relevant for researchers interested 
in apoptosis and useful as a testing platform for ultrasound/microbubble tissue disruption. 
 
5.3.4 Patterning of Microbubbles with ATPS 
Patterning techniques are frequently used in biomedical research for performing cell co-cultures, 
migration assays, wound healing assays, therapeutic targeting experiments and high throughput 
analyses. A variety of approaches have been developed for controlling placement of cells, 
including selective patterning of substrate materials, and direct cell printing with inkjets, and 
more recently ATPSs (Ringeisen et al. 2006, Wright et al. 2007, Tavana et al. 2009, Tavana et 
al. 2010). These technologies are useful for spatially organizing cells, but some cell types require 
patterning in situ (i.e., they are already growing on a surface). This is often the case for primary 
cells that have strict substrate requirements and a limited potential to divide in vitro. There are 
relatively few technologies that permit patterning on cells already growing as monolayers. ATPS 
micropatterning is capable of this type of patterning due to its biomolecule and particle 
partitioning ability (Tavana et al. 2009, Albertsson 1986). Here, we demonstrated that ATPSs 
can be used to deliver microbubbles to preformed monolayers of cells. 
Physical disruption of the plasma membrane can be achieved by microinjection, 
hydrodynamic delivery, magnetotransfection, laser poration, ballistic delivery and 
electroporation, in addition to sonoporation (Villemejane and Mir 2009). Among these methods, 
electroporation and sonoporation are two of the most effective physical methods for disrupting 
membrane integrity (Wells 2010). However, neither technique is traditionally amenable to 





ATPSs to confine microbubbles, which are known to be highly effective sonoporation 
facilitators. 
Our ATPS microbubble patterning strategy provides several advantages for sonoporation. 
First, it provides an easy way to precisely place microbubbles in close vicinity to cells, thereby 
providing a controlled sonoporation platform. In our system, the microbubbles reside directly 
above the cells and are well dispersed in the XY dimensions, as confirmed by brightfield 
microscopy and our observations that microbubbles are in nearly the same focal plane as cells. 
This allowed us to overcome one of the main challenges in sonoporation research, the inherent 
unpredictability associated with free-floating micro- bubbles and controlling their impact on 
cells. Conventionally, sonoporation experiments have been conducted in centrifuge tubes or Petri 
dishes, where microbubbles are freely floating in the bulk solution (Zhong et al. 2011). In these 
systems, the relative locations of the microbubbles and the cells are random and cannot be 
controlled. In some sonoporation experiments, cells are cultured inside thin chambers (e.g., 
Opticell). To ensure microbubbles are in contact with the cultured cells, these thin chambers are 
positioned upside down so that microbubbles float up to the adherent cells (Meijering et al. 
2009). However, this approach often leads to clustering of microbubbles at the boundaries of 
cells due to differences in the height of cells across the cell monolayer. In these systems, it is 
difficult, if not entirely impossible, to target a small region or sub-population of cells. 
In our approach, the microbubbles can be easily positioned on any target cell population 
at controlled spatial locations. In most types of ultrasound experiments, long sonoporation treat- 
ment durations are used to maximize the chance of free-floating microbubbles impacting the 





ultrasound durations; therefore, the microbubble dynamics are better controlled without large 
translational movements due to effects such as microstreaming. 
Our system can be used for cells that grow on virtually any substrate, making this 
approach more versatile and adaptable. The ATPS medium itself imposes no acoustic 
discontinuity above the cells while confining the bubbles within a fluid (this is problematic for 
most microdevices). In addition, our approach reduces the amount of reagent and the number of 
microbubbles by as much as 10 000-fold because microbubbles are confined in 0.1 µl DEX 
droplets instead of 10 ml solutions used in conventional sonoporation experiments in a dish or 
similar container. Since we use small amounts of microbubbles and can generate well-defined 
patterns, this approach is highly amenable to multiplexing ultrasound parameters, the 
microbubble type/ concentration, and the concentration and type of biomolecule present in the 
extracellular space. The final advantage of our system relates to the need for 
antibody/microbubble conjuga- tion. For targeted microbubble applications, antibody conjuga- 
tion is needed to ensure microbubble targeting and attachment to the cell surface. Our approach 
does not require antibodies for targeting cells because the DEX droplets confine the 
microbubbles at the cell surface. This allows the same microbubbles to be used with any cell 
type without any modification. 
 
5.3.5 Implications for Apoptosis Research 
Patterning of microbubbles using ATPSs provides a novel system with great potential for new 
bioapplications. In this study, we used ATPS microbubble patterning for selectively inducing 
apoptosis. A number of studies have shown sonoporation induced apoptosis in cells, although the 





2010). Moreover, in sonoporation-mediated gene delivery experiments, a large number of cells 
are often damaged or killed by ultrasound-activated microbubbles, although the number of dead 
cells and the mechanism of their death (i.e., apoptosis vs necrosis) are not always clearly 
reported in the literature. In our study, the spatial localization and patterning of microbubbles 
using ATPS enabled detailed investigation of ultrasound excitation of microbubbles and their 
effects on the cells. With ATPS microbubble patterning, we induced a high proportion of cells to 
enter apoptosis in targeted areas within a monolayer by inducing calcium influx into the cells 
during sonoporation. Based on our previous experiments using DEX as a delivery vehicle for 
lipofection agents, the DEX and PEG polymers have little to no effect on cell viability. 
Therefore, apoptosis was mediated by microbubble-induced membrane damage and cal- cium 
influx, as evidenced by a dose response to extracellular calcium. This example illustrates that our 
technology of ATPS microbubble patterning may be used as a potential platform for studying 
apoptosis through transmembrane delivery of ionic or chemical initiators of apoptosis. Since our 
technique facilitates multiplexing of both microbubble condition and ultra- sound treatment for 
testing the effects of sonoporation on cell viability, this may be useful for studying localized cell 
injury or apoptosis, while testing a wide range of treatments or acquiring a large number of 
independent observations (Douville et al. 2011). 
  Apoptotic cells are recognized and removed by resident macrophages in tissue; whereas 
damage caused by necrotic injury is not recognized by the immune system and can lead to 
toxicity in the surrounding tissue (Wickman et al. 2012). Since apoptosis is highly localized to 
specific cell populations in our system, ATPS microbubble patterning for ultrasound excitation 
may serve as a useful test system for investigating the interactions of apoptotic cells with 





remove debris. The effect that dying cells have on neighboring healthy populations can also be 
readily investigated in our system. Furthermore, by using ATPS and microbubbles to locally kill 
cells it will be possible to perform well-controlled wound healing assays without physical 
removal of the damaged region. In our system, the wounded region consisting of both apoptotic 




It will be useful to design easier to use setups to dispense the DEX droplets and apply ultrasound 
excitation to microbubbles. Development of new microbubbles that partition better in DEX can 
also help to improve and expand this technology. Finally, our technology may serve as a useful 
high throughput testing platform to investigate the mechanisms for various microbubble-
potentiated ultrasound applications such as ultrasound mediated drug delivery for cancer 
treatment, as well as ultrasound tissue ablation, where fractionation, necrosis and enhanced 









Figure 5.1: Patterned sonoporation is achieved by depositing DEX droplets, containing 
microbubbles on cell monolayers in a PEG/DEX ATPS. (A) Microbubbles are dispensed onto 
cells in PEG using a glass capillary needle. (B-C) The ultrasound transducer is used to activate 
the bubbles, which are contained within the DEX phase. (D-F) High magnification images of a 
single microbubble in DEX attached to a single cell (as indicated by the black arrows) before, 
during, and after ultrasound application captured with a high speed camera. This bubble was 
activated upon ultrasound treatment, undergoing rapid expansion and contraction, which resulted 
in bursting/shrinking on the cell, as visualized using ultrafast videomicroscopy. As microbubbles 
expand and contract during ultrasound application at 1.25 MHz, halos appear around the 
microbubbles due to rapid volume (E).  After microbubble activation, the microbubbles 
disappear or become smaller in size (F). (G) Microbubbles can be patterned with various user-
defined array geometries, as indicated by patterning of a Michigan “M”, visualized with 
intracellular PI staining after microbubble excitation. (H) Apoptosis was selectively induced in 
the microbubble patterned regions treated with ultrasound (0.6 MPa, 8 µsec pulse) as indicated 
by annexinV (green) and PI (red) staining after ultrasound treatment. All images are for non-









Figure 5.2: Partitioning of microbubbles. (A) The percentage of microbubbles present in DEX, 
at the PEG/DEX interface and in PEG was calculated for various ATPS formulations with 
different DEX molecular weight. DefinityTM microbubbles localized to the interface and the PEG 
phase, whereas Targestar-SA microbubbles localized to the interface and the DEX phase for 
lower molecular weight of DEX. Bars denote mean ± SEM. (B) Microbubbles that were 
deposited within DEX droplets and tracked by video microscopy confirmed the results in (A). 
DefinityTM bubble collected at the PEG/DEX interface and eventually crossed the interface to 
enter the PEG phase. Targestar-SA microbubbles were well-retained in DEX. Scale bar ~ 60 µm. 
(C) Droplets of DEX containing DefinityTM microbubbles could not mediate transmembrane 
delivery of PI in HUVECs. Droplets with Targestar-SA microbubbles mediated PI delivery with 








Figure 5.3: Optimization of ultrasound and microbubble conditions for targeted cell killing. (A) 
Placing DEX droplets in an array allows multiplexed testing of ultrasound parameters such as 
number of pulses (down) and pressure amplitude (across). The array image is a reconstructed 
mosaic from high magnification brightfield and PI images. Scale ~ 500 µm. Cell death was 
minimal at low pressures (0.1 and 0.2 MPa). Multiple low pressure pulses (3 or 4 pulses) resulted 
in a slight increase in cell death for the 0.2 MPa ultrasound condition. Pressures of 0.4 and 0.6 
MPa resulted in a high proportion of cells dying in the patterned areas, with little effect from 
additional pulses. (B) Decreasing the DEX concentration resulted in microbubble aggregating. 
Cell death was markedly reduced at 8% and 4% DEX concentrations. (C) The proportion of dead 
cells decreased with decreasing microbubble concentrations. (D) HUVECs were most sensitive 
to microbubble excitation, but cell death was similar among all the cell types we tested. Control 
regions without microbubbles showed minimal cell death (data compiled for all cell types). Bars 
in (B-D) denote mean ± SEM for n= 3 independent experiments. (E) Time lapse imaging of 
microbubble targeted co-cultures of MDA231, NIH 3T3 and HUVECs showed that cell debris 
was gradually removed over the course of several days as the treated regions became repopulated 







Figure 5.4: Effects of ultrasound excitation of microbubbles on HUVECs. (A) Treated cells 
displayed a variety of apoptotic morphologies. Red signal corresponds to PI nuclear staining and 
green signal corresponds to annexinV staining. (B) Ultrasound activation with low pressure (e.g. 
< 0.3 MPa) for a long treatment duration resulted in a low percentage of cells dying from 
apoptosis. (C) Short ultrasound pulses at high pressure amplitudes (e.g. 0.4 MPa and 0.6 MPa) 
resulted in significantly higher percentages of cell dying from apoptosis. Bars in (B, C) denote 
























Figure 5.5:  Effects of extracellular calcium concentration on apoptosis in microbubble patterned 
cultures. PI labeling of dead cells (A) and annexinV labeling of apoptotic cells (B) increased in 
the presence of high extracellular calcium (≥ 5mM).  Solid lines represent 0.3 MPa ultrasound 
pressure, dashed lines represent 0.6 MPa ultrasound pressure and black lines represent no 
ultrasound treatment. Bars denote mean ± SEM for n>3 independent experiments. (C) 
Representative images of sonoporated cells in the presence of Cytomix buffer (no free 
extracellular calcium) for various ultrasound conditions. (D) Representative image of 
sonoporated cells in the presence of 5 mM calcium buffer for various ultrasound conditions. (E) 
Fura-2AM ratiometric calcium imaging of HUVECs treated with either 0 or 5 mM calcium and 
either 0.3 or 0.6 MPa ultrasound pressure, along with representative images taken at frame 45 of 
imaging (shortly after the ultrasound pulse). Bars denote mean ± SEM.  (F) JC1 staining for 
control (no ultrasound) and ultrasound-treated cells.  Red staining indicates normal 
mitochondrial membrane potential and green staining indicates loss of membrane potential. (G) 
Cell Event caspase staining for control (no ultrasound) and ultrasound-treated cells.  Green 
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High-throughput Aqueous Two-Phase Printing of Contractile Collagen Gels 
 
This chapter describes a simple, micropatterning approach to generate a high throughput 
contractile contraction assay. Briefly, cell-containing collagen microdroplets are spatially 
patterned and confined within droplets of immiscible aqueous polymer solutions. The fully 
aqueous conditions enable convenient formation of sub-microliter ‘microgels’ that are much 
smaller than is otherwise possible to make while maintaining high cell viability. The produced 
microgels contract over several days, mimicking the behavior of macroscale contraction assays 
that have been valued as an important biological readout for over three decades. Utility of the 
technology is demonstrated by analyzing the effects of TGF-β1 on gel contraction, and we 
demonstrate that brief ‘burst’ stimulation profiles in microgels prompts contraction of the matrix, 
a feature not observed in the conventional macroscale assay. The fully aqueous process also 
enables the integration of contractile collagen microgels within existing cell culture systems, and 
we demonstrate proof-of-principle experiments in which a contractile collagen droplet 
mechanically damages an epithelial monolayer. The simplicity, versatility and ability to robustly 
produce collagen microgels should allow effective translation of this microengineering 








The ability for a cell to remodel the surrounding extracellular matrix (ECM) is a critical feature 
in development, homeostasis and disease progression.  In particular, cell-mediated contraction of 
collagen matrices occurs in a variety of situations including embryo development, wound 
healing, and the formation of fibrotic scars and lesions (Lee et al. 2012; Rolfe et al. 2012; de 
Vlaming et al. 2012; Shannon et al, 2006; Grinnel 2003; Carlson and Longaker 2012; Ehlrich 
and Hunt 2012; Wong et al. 2012). In vitro collagen contraction assays have provided important 
insights into biological processes, by enabling the production of tissue-like structures that may 
serve as engineered replacements or as model systems to investigate disease pathologies (Bell 
and Merrill 1976, Feng et al. 2003; Bell et al. 1981; Cen et al. 2008; Bowles et al. 2010; West et 
al. 2012; Yip et al. 2009; Eldred et al. 2011; Tse et al. 2004). Since the collagen contraction 
assay is simple to perform, captures relevant physiological details, and is broadly applicable in a 
variety of processes, it has remained an important research tool for over three decades.  
However, the complex mechanism driving the matrix contraction process, is combinatorially 
influenced by multiple environmental factors, including the structure of the collagen matrix, the 
presence of soluble cytokines, and the type and density of cells driving the process (Tse et al. 
2004; Smith et al., 2006; Zhu et al. 2001; Tingstrom et al. 1992; Riikonen et al. 1995; 
Montesano and Orci 1988; Wong et al. 2000, Gabbiani 2003; Li et al. 2007).  Given the number 
of potential combinations of biological variations that influence contraction, there exists a need 
for high-throughput versions of this assay, particularly for applications in drug screening and 
personalized medicine. 
Several limitations prevent the translation of this assay to a high-throughput format.  Each 





ml in a 35 mm dish) to enable facile handling (Gulberg et al. 1990; Timpson et al. 2011).  This 
volume of material requires a correspondingly large number of cells to maintain a sufficient 
density to contract the collagen matrix, limiting the use of this assay to relatively low-throughput 
systems for which a sufficiently large supply of cells is easily available (Redden et al. 2003).  
This makes it challenging to use this assay for applications involving primary cell culture, or for 
personalized medicine, in which large scale expansion of isolated cells may cause significant 
phenotypic drift (Yao et al. 2006). Furthermore, the relatively large volume of collagen gels limit 
diffusive transport, particularly of high molecular weight growth factors, known to play a 
significant role in influencing collagen matrix contraction (Wong et al. 2000; Raghavan et al. 
2010). Hence, despite the established role of timing in the application of signaling molecules to 
cells in the body the large sample volume prevents uniform activation of cells within the matrix 
by the application of burst or pulsed biochemical stimuli (Jovic et al. 2009).   
Reducing the initial size of the collagen gels may address these concerns, but fabricating 
‘microgels’ can pose significant technical challenges.  While gel microdroplets are achievable in 
a variety of materials, most processes depend on rapid polymerization of the droplets (Elbert 
2011; Wann 2012).  Collagen hydrogels are conventionally not amenable to such schemes, as the 
polymerization mechanism is pH-sensitive, thermally driven and relatively slow (Forgacs et al. 
2003). Once neutralized, collagen solutions require time at elevated temperatures to undergo 
complete gelation, with different protocols recommending gelation times from 30 minutes to 12 
hours (Fischer et al. 2012). While this timeframe presents few concerns in polymerizing large 
volumes, small droplets are susceptible to a significantly greater degree of evaporation, which 
can impact cell viability and functionality.  Careful control over processing conditions is 





mediated by polymerizing the collagen in an oil-water system, the thorough wash steps required 
add time, complexity and uncertainty to the assay (Vernon et al. 2002; Solorio et al. 2010).  
Alternatively, small volumes of collagen have been patterned using microfluidic flow systems, or 
via a microfabricated template to produce small gels within confined boundaries (Raghavan et al. 
2010; Legant et al. 2009; Zhao et al. 2013). Each of these techniques requires a substantial 
investment in microfabrication-related tools, peripherals and expertise, and is therefore 
challenging to translate into conventional wet-labs. 
To simplify the formation of collagen microgels, we demonstrate an approach to maintain 
collagen in a distinct droplet during the polymerization process, within an aqueous environment.  
We utilize an aqueous two-phase system (ATPS), in which soluble polymers thermodynamically 
drive aqueous systems to form two distinct phases.  Our research group and others have 
demonstrated that biomolecules can selectively partition to one of the phases, and we have 
previously used this phenomena to position and maintain biomolecules on living cells (Tavana et 
al. 2009; Albertsoon 1987). In the present work, we demonstrate that collagen matrix 
components selectively partition to the interface of a poly(ethylene) glycol / dextran aqueous 
two-phase system (Fig. 6.1C); and exploit this finding to successfully polymerize sub-microliter 
volumes of cell-laden collagen microdroplets, within an aqueous environment (Fig. 6.1A-B).  
We demonstrate this technology as a simple, versatile and easily managed approach to simplify, 
increase throughput and extend the capabilities of the widely used collagen matrix contraction 
assay.  While this system is also compatible with more advanced technologies such as high-
throughput bioprinters, automated liquid handlers, and microfluidic systems, a simple manual 





2010).  Hence, we envision this aqueous two-phase approach to collagen printing as being 
broadly applicable in a variety of contexts. 
 
6.2 Materials and Methods 
Unless otherwise stated, all chemicals and reagents for cell culture were purchased from Sigma-
Aldrich, fluorescent dyes from Invitrogen and all other equipment and materials from Fisher 
Scientific.   
6.2.1 Cell culture 
Four cell types were used in these experiments:  HEK 293 embryonic kidney cells; NIH 
3T3 murine fibroblasts; MC3T3 murine osteoblast precursors cell line; and MCF10A epithelial 
cells.  HEK 293 and NIH 3T3 cells were cultured in fully supplemented Dulbecco’s Modified 
Eagle Medium (DMEM, with 10% heat-inactivated Fetal Bovine Serum (FBS), 1% antibiotics-
antimycotics).  MC3T3 cells were cultured in fully supplemented Alpha Minimum Essential 
Media (αMEM with 15% FBS, 1% antibiotics-antimycotics) in an incubator (37 °C, 5% CO2).  
MCF10A cells were cultured in Mammary Epithelial Growth Medium (MEGM; Lonza).  Cells 
were not allowed to reach confluence, and sub-cultured in 1:10 ratios by trypsinization.  When at 
desired confluence, cells were washed with phosphate buffered saline (PBS) and 0.25% trypsin 
solution was added to the flask.  Cells were incubated for 5 minutes, and then harvested and 
centrifuged (1000 RPM, 5 minutes) in a conical tube.  The supernatant was aspirated and the cell 
pellet was re-suspended in fully supplemented culture medium.  For ATPS-collagen 






6.2.2 Preparation of aqueous two-phase system reagents 
Stock solutions of DEX (20% w/w dextran T500, Pharmacosmos) were prepared in PBS 
on a rocker overnight, and centrifuged at 3000 RPM for 15 minutes to remove any undissolved 
particulates.  A stock solution of PEG (20 wt%, MW: 35 kDa, Fluka) was prepared in fully 
supplemented culture media, and centrifuged.  Both stock supernatants were removed and passed 
through a 0.22 µm sterilizing syringe filter.  PEG stock solutions were then diluted to working 
concentrations in fully supplemented culture medium, and balanced to 300 mOsm/kg by the 
addition of sterile deionized water, as measured with an osmometer (Vapro 5520 Vapor Pressure 
Osmometer; Wescor).  PEG working solutions were stored for up to 2 weeks at 4 °C.  Collagen-
DEX solutions were prepared by diluting Type I bovine collagen (BD Biosciences) to 2 mg/ml in 
a sterile solution of 10% v/v 10x DMEM, 1% v/v 3M NaOH, 15% v/v DEX stock solution (to a 
final concentration of 3% dextran) and 7.3% v/v additional buffer.  Depending on the experiment 
performed, the buffer solution was either DMEM or a suspension of cells in fully supplemented 
DMEM.  Neutralized collagen-DEX solutions were stored on ice for a maximum of 30 minutes 
before use. 
 
6.2.3 Production of ATPS-collagen droplets 
Working solutions of PEG were warmed to 37 °C and pipetted into a 48-, 96- or 384- 
well plate depending on the assay being performed.  For manual production of droplets, 
collagen-DEX solutions were maintained on ice and pipetted directly into the PEG-enriched 
media.  We experimentally found that rapid expulsion of the droplet from the pipette tip led to 
more uniform collagen droplets.  Automated production of droplets was performed using a 





and loaded with collagen-DEX solution, and kept cold during the dispensing process using an 
ice-pack.  The tip magazine was loaded with 96 sterile pipette tips (25 µl, CyBio), programmed 
to aspirate and dispense a desired volume into the target plate from a height of 1 mm above the 
plate surface.  Following dispensation of the collagen-DEX solution, the plates were placed in an 
ambient air incubator at 37 °C for 30 minutes to allow the collagen to crosslink fully.   The PEG-
enriched medium was then carefully aspirated, and the droplets were carefully washed with PBS 
and maintained under fully-supplemented culture medium with or without additional soluble 
factors.  When applicable, medium was supplemented with varied concentrations of 
Transforming growth factor (TGF)-β1 (R&D Systems).  As a final step, the solutions were 
pipetted rapidly to dislodge the collagen droplet from the underlying surface, before culture for 
up to 15 days. 
 
6.2.4 Fluorescent labeling, imaging and analysis 
Collagen microgels were imaged at selected timepoints using a standard inverted 
microscope (TE300, Nikon) and a 4x objective.  Measurement of collagen droplet area was 
performed by analysis of binary threshold images, using a semi-automated script in ImageJ 
(NIH).  For viability assays, cells were encapsulated in collagen droplets, and at the appropriate 
time point, the surrounding media was replaced with 4 µM Calcein-AM and 2 µM Ethidium 
Homodimer (EtHD) in PBS for 30 minutes.  The media was washed away and droplets were 
fluorescently imaged to assess viability.  Percent viability was calculated as the number of cells 
labeled with Calcein AM, divided by the total number of cells identified with Calcein AM and 
EtHD.  To distinguish between cell populations, CellTracker dyes were used to label cells as per 





fixed in 4% paraformaldehyde for 20 minutes at room temperature, permeabilized with 0.1% 
triton-X for 10 minutes, and fluorescently stained for actin structures using FITC-phalloidin.  
Fluorescently labeled cells were imaged with a confocal microscope to confirm even distribution 
through the hemispherical gel. 
 
6.2.5 Statistical analysis 
All statistics are reported as means ± standard deviation.  ANOVA tests were performed 
using a commercially-available software package (SigmaStat 3.5; Systat Software Inc., San Jose, 
CA), using the Tukey test for post-hoc pairwise comparisons.    
 
6.2.6 Scanning electron microscopy 
 Droplets of collagen were prepared in ATPS as described, and allowed to polymerize for 30 
minutes on a glass coverslip.  The droplets were gently washed in PBS three times, and then 
rinsed and stored in DI water.  Samples were snap-frozen in liquid nitrogen, lyophilized, and 
coated with 10 nm of gold using a plasma-induced sputter deposition system.  Samples were 
loaded into an XL30 FEG scanning electron microscope (Philips), and imaged at 5000x, with a 
beam voltage of 5 kV, and spot size of 3.  Images were analyzed for fiber sizes using ImageJ, 
and expressed as a mean ± standard deviation (n = 3).   
 
6.2.7 Determining collagen partitioning behavior 
Partitioning of collagen within the aqueous two-phase system was determined by a dot blot 





quantities of PEG and dextran.  Acidic collagen solution was prepared by mixing 20 µL 10X 
PBS, 33.3 µl of collagen stock solution, 30 µl of 20 wt% DEX, 116.2 µl 0.02 N acetic acid, and 
200 µl 10% PEG in an Eppendorf tube.  After centrifuging at 400 rcf for 7 mins, the PEG, 
interface and DEX phases were separated and 20 µl of each phase was diluted in 20 µl 0.02 N 
acetic acid. Small strips of polyvinylidene fluoride (PVDF) membranes (Bioexpress) were placed 
on the surface of methanol for 15 seconds. Then membranes were washed in distilled water for 2 
minutes and PBS for 5 minutes.  0.2 µl samples of the diluted PEG, interface and DEX phases 
were spotted onto the wet PVDF membrane. The membrane was rinsed in distilled water and 
then transferred to solution containing Coomassie Blue stain for 10 minutes (0.2 % (w/v) 
Coomassie Blue, 40% (w/v) methanol, 10 %(w/v) acetic acid).  The membrane was then de-
stained for 3 minutes in 80 % (w/v) methanol/10 %(w/v) acetic acid.  Finally, the membrane was 
placed in a second de-staining solution for 1 hour (45 %(w/v) methanol/10 %(w/v) acetic acid).  
Brightfield images showing Coomassie-stained collagen were analyzed based on intensity levels 
and reported as arbitrary units. 
 
6.2.8 Mass transport simulations 
A commercially available finite element package (COMSOL v4.3; Burlington, MA) was used to 
simulate diffusion in ATPS-generated collagen droplets and in the conventional collagen assay, 
similar to previous work by Raghavan et al. (Raghavan et al. 2010).  The geometry of a 5 µl 
droplet was experimentally determined and modeled as an axisymmetric hemisphere with a 1.75 
mm diameter.  The conventional assay for collagen contraction was modeled as a cylinder with 
diameter 6.38 mm and depth 3.125 mm.  The diffusion coefficient for TGF-β1 in collagen was 





(MW 65kDa), and the Stokes-Einstein equation for diffusivity of particles.  A boundary 
concentration was applied to the outside of the droplet, and a time-stepped transport of diluted 
species analysis was conducted to determine concentrations of TGF-β1 in the center or bottom of 
the collagen droplet or cylinder. 
 
6.3 Results and Discussion 
6.3.1 Characterization of collagen microgels 
Dot blot tests reveal that collagen selectively partitions to the interface of a 3% dextran T-500 
(DEX) / 5% polyethylene glycol 35k (PEG) system, with a partition coefficient of 0.011 +/- 
0.005 (n = 3; Fig. 6.1).  The partition coefficient is defined as the fraction of collagen that 
remains in the PEG phase, compared to the DEX and interfacial regions.  Since the DEX-
enriched phase is denser than the PEG phase, it sinks to the bottom of the two-phase system.  
Although these measurements indicate that collagen selectively partitions to the interface, when 
the DEX droplet becomes sufficiently small, the accumulated collagen at the interface forms a 
hemispherical dome.  The formation of a complete hemispherical dome was verified by visual 
inspection, and through cross-sectional views generated by confocal microscopy of fluorescently 
labeled embedded cells.  Scanning electron microscopy (SEM) of the collagen fibers indicate 
consistently uniform fiber sizes (70 +/- 24 nm; n =3; Fig. 6.2A), consistent with collagen fiber 
diameters produced in conventional collagen gelation schemes.  Introducing a low concentration 
of mouse fibroblast cells into the collagen droplet appears to locally increase pore size and 
increase collagen fibril diameter around the cells after one day in culture (Fig. 6.2B), consistent 
with the accepted mechanism by which cells compact collagen matrices (Stevenson et al. 2010; 





ATPS-collagen droplets dispensed into well-plates demonstrate that the resulting collagen 
microgel dimensions depend on the volume of dispensed DEX/collagen solutions.  Droplets were 
dispensed using either a manual pipette, or an automated liquid handler system (CyBi Well; 
CyBio Inc.).  The lateral microgel dimensions are similar to those expected for ideal hemispheres 
(Fig. 6.2C), with similar results if collagen droplets are formed on bare tissue-culture plastic 
(TCP) surfaces, or on a monolayer of viable HEK 293 cells.  Our previous work indicated that 
the presence of cells on the substrate alters the interfacial tension between the two phases, 
prompting differences in droplet spreading; but this appears to be abrogated in the collagen 
ATPS (Tavana et al. 2011).  Though differences do exist between droplets plated on TCP and on 
cells, the difference is minimal, particularly at smaller droplet volumes.   
Microgel dimensions are also affected by the concentration of PEG in the media.  At 
concentrations less than 5%, droplets do not form, and droplets appear to take a more 
hemispherical shape at concentrations greater than 6%.  While the possibility of long-chain PEG 
molecules interfering with cell function is low due to the excellent resistance of PEG to non-
specific binding, all further experiments were conducted at the lowest robustly stable 
concentration to minimize any potential interactions with cells (Jain et al. 2012).  Microgel 
dimensions are also influenced by concentration of collagen in the droplet (Fig. 6.2D), 
suggesting that collagen plays a role in thermodynamically driving separation in the ATPS 
system.  This is supported by the fact that the minimum concentrations of DEX and PEG 
required to form two phases without a collagen component is greater than the concentrations 






6.3.2 Cell viability and contraction assays  
NIH 3T3 cells were used as a model cell line to evaluate viability of cells encapsulated in ATPS-
collagen microgel production.  Two initial potential polymerization schemes were tested and 
evaluated for cell viability.  In the first, the acidic collagen-DEX component was neutralized 
before the addition of cells.  In the second, cells were mixed with the acidic collagen-DEX 
component and immediately dispensed into the PEG-enriched medium, where the droplet would 
neutralize because of the greater volume of the surrounding media.  While this approach would 
eliminate the possibility that the collagen-DEX would polymerize before being dispensed, 
viability stains indicate that cell viability is significantly impacted using the acidic method (p < 
0.001 after 24 hours, n = 5; Fig. 6.3C).   
To compare the ATPS-mediated approach with conventional collagen gelation protocols 
in fabricating low-volume gels, viability of cells in 1 µl droplets was tested 8 hours after droplets 
were made using each method.  When 1 µl droplets were placed on the surface of a Petri dish 
(without an aqueous environment) and polymerized at 37 °C for 30 minutes viability of cells 
significantly decreased as compared to those droplets allowed to polymerize within an ATPS (p 
< 0.001, n = 10; Fig. 6.3D).  This is likely due to evaporation of water from the droplets and a 
consequent increase in osmolality during the time necessary for polymerization. While the 
conventional process may be optimized for time and humidity, this data demonstrates that such 
considerations are not necessary when preparing collagen droplets in an aqueous two-phase 
system. 
Sufficiently large concentrations of cells within the collagen microgel cause contraction 
of the matrix over several days when the matrix is released from the surface (Fig. 6.4A-B).  





medium at the droplet during the final washing step of the assay.  Contraction rates are strongly 
dependent on cell type, with HEK 293 cells at 1 million cells / ml providing the smallest 
contraction over 2 days, and MC 3T3 pre-osteoblasts at the same concentration forcing the 
largest matrix contraction (Fig. 6.4C).  As MC 3T3 pre-osteoblasts provided the greatest 
contraction, all further experiments were conducted using this cell type.  These differences 
demonstrate that the ATPS-mediated production of collagen microgels maintains sensitivity of 
the assay in measuring contraction of the collagen matrix. 
Comparisons between the conventional collagen contraction assay performed with 100 
µL of cell-laden collagen in a single well of a 96-well plate and various droplet sizes fabricated 
using the ATPS production method, indicated that contraction of collagen was not significantly 
affected by the size of the collagen construct (p = 0.124; Fig. 6.5A), demonstrating that scaling 
down the assay volume still provides readouts comparable with the conventional technique 
(Gullberg et al. 1990).  As expected, cell density plays a key role in mediating collagen 
contraction (Fig. 6.5B).  Collagen droplets expanded slightly when cultured without cells, while 
a low concentration of 50 cells / µl maintained droplet size over 4 days.  Greater cell 
concentrations caused rapid contraction of the droplets, consistent with reports in conventional 
assays (Redden and Doolin 2003).  To characterize the effect of PEG on the contraction system, 
collagen microgels were maintained in PEG-enriched media of different concentrations over 
several days.  Interestingly, greater PEG concentrations resulted in reduced levels of contraction 
(Fig. 6.5C), suggesting that PEG interferes with the contraction process, either via a cell-
mediated mechanism, or by direct mechanical augmentation of the contracting collagen matrix. 
Cell-mediated contraction of the collagen matrix is also influenced by the presence of 





low as 1 ng/ml were sufficient to prompt a rapid increase in contraction of the collagen 
microgels.  Concentrations greater than 1 ng/ml had no statistically significant effect on 
contraction rates (Fig. 6.5D).  Taken together, these data demonstrate that fabricating collagen 
microgels via an aqueous two-phase production method produces similar responses as compared 
to the conventional assay. 
 
6.3.3 Exploiting transport properties of microgels 
To demonstrate the potential for microscale systems in improving transport of large molecules 
such as TGF-β1 (MW 25 kDa) into the collagen matrix, finite element simulations were used to 
compare passive diffusion of large molecules in the conventional assay (100 µl of collagen in a 
96-well plate cylindrical form) against the ATPS-mediated production of microgels (5 
µlhemispherical droplets; Fig. 6.6A, B).  Concentration of the diffusing molecule reaches at least 
90% of equilibrium throughout the construct within 30 minutes in the ATPS droplet, while the 
conventional assay reaches 90% equilibrium after 28 hours; demonstrating that while the 
conventional collagen contraction assay responds to applied soluble cues, this response is not 
necessarily homogenous throughout the system, nor does the system allow for burst or timed 
stimulation by soluble cues.  Equilibration of smaller droplets occurs much more rapidly.  As 
timed stimulation is emerging as an important feature in mimicking in vivo physiological 
systems, extending the collagen contraction assay to include a time-dependent component may 
yield interesting insights into the biology of such systems (Jovic et al. 2009).   
To explore the possibilities in using this system to apply dynamic stimulation profiles of 
large molecules to cells within the collagen matrix, we applied timed TGF-β1 stimulation 





polymerization and rinsing of the microgels, they were exposed to 1 ng/mL of TGF-β1 for short 
bursts of time, before washing the gels thoroughly with PBS and allowing them to contract for 1 
day.  At equilibrium conditions, 1 ng/ml of TGF-β1 was sufficient to induce increased 
contraction of the collagen matrix within this time frame (Fig. 6.5D); and even extremely rapid 1 
minute exposures to this concentration of TGF-β1 was sufficient to induce increased levels of 
contraction in ATPS-mediated gels.  In contrast, even 5 minutes of exposure was not sufficient to 
prompt a similar effect in the conventional assay.  This data indicates that penetration of collagen 
into the large gels is minimal, while penetration into the microgels is completed in a fraction of 
the time.  Hence, utilizing collagen microgels in the contraction assay enables rapid stimulation 
of cell culture constructs for timed stimulation studies. 
Though this effect will be less noticeable with smaller molecules, the ability to remove 
molecules from the assay will also be of importance in timed stimulation assays.  To demonstrate 
such an application, contracting microgels were exposed to Latrunculin-A, known to disrupt the 
actin filaments of the cytoskeleton, and hence abrogate contraction of the tissue construct.  24 
hours of exposure to Latrunclin A (or Nocodazole, a microtubule disruptor; data not shown) 
prevented collagen contraction, but limiting exposure to 60 minutes enabled the microgels to 
recover their contractile ability, showing no significant differences from the control (p = 0.513; 
Fig. 6.6D).   
 
6.3.4 Utility of the system within existing tissue-engineered models 
In addition to exploiting transport properties resulting from the ability to produce low volume 
gels, aqueous two-phase mediated patterning of contractile collagen gels also enables the 





used to rapidly and easily produce complex engineered tissues, in which cell-laden collagen gels 
are patterned over an existing cell monolayer (Fig. 6.7A).  Hypothetically, this approach can be 
extended to build several layers of droplets containing multiple cell types in well-defined 
patterns.  This approach may also be used to introduce a contractile collagen microgel into an 
existing cell culture model system, to provide a cell-based functional readout for signaling 
factors produced in that system.  As our approach uses fully aqueous environments, this 
technique should be broadly applicable to all cell culture systems.  To demonstrate proof-of-
principle of this technique, we patterned contractile collagen microgels containing MC 3T3 pre-
osteoblasts over a confluent monolayer of MCF10A breast epithelial cells (Fig. 6.7B-C).  The 
epithelial cell sheet is a simple cell culture system, characterized by tight junctions between cells.  
After four hours in culture the collagen microgel contracted sufficiently to damage the 
underlying epithelium (Fig. 6.7C-D).  Damage occurs close to the contractile droplet, while 
areas further away remain intact, strongly suggesting that the mechanical insult provided by the 
contractile droplet rips the epithelial monolayer from the substrate.  This simple co-culture 
system enables the study of mechanical interactions between different tissue types, and may be 
used to simulate certain physiological processes, such as in development or wound healing in the 
airways.  Furthermore, this approach may also be used to measure the influence of soluble cues 
generated by relevant cell culture model systems on contraction of an in situ collagen microgel.  
 
6.4 Conclusion 
Aqueous two-phase systems have been used for a variety of biotechnology applications, and here 
we demonstrate the use of this approach to produce sub-microliter volumes of collagen 





system, and undergo gelation in an aqueous environment, such that hemispherical microgels can 
be produced on a variety of substrates, including on live cell monolayers.  The aqueous 
environment prevents evaporation within the small droplet volume, allowing encapsulated cells 
to remain viable.  In contrast, similarly sized gels polymerized using the conventional approach 
in air suffered significant losses in cell viability.  When a sufficiently large number of contractile 
cells are encapsulated in the droplet, the matrix undergoes remodeling and contraction, at a rate 
dependent on cell type, cell density, and the presence of soluble factors; mimicking results in 
conventional macroscale collagen contraction assays.  The ability to use collagen microgels for 
contraction assays not only reduces the volume of reagents and number of cells necessary, but 
also significantly improves transport of molecules into the bulk of the hydrogel droplet.  Hence, 
collagen microgels may be used to conduct time-dependent and pulsed stimulation, which would 
not be possible with conventional approaches.  Finally, the aqueous two-phase processing system 
also enables production of collagen microgels within existing cell culture environments, and may 
be used as either a tool to print complex three-dimensional engineered tissues, or to conduct 
collagen contraction assays in situ.  We demonstrate that the system is scalable to high-
throughput screening applications by using an automated liquid handler system, and believe that 






Figure 6.1:  Aqueous two-phase patterning of collagen droplets.  (A) Process schematic in which 
a droplet of DEX-rich collagen is dispensed into a PEG-rich media, allowed to settle, and 
undergo thermal gelation.  (B) A 1 µl collagen droplet after gelation in an ATPS, scale bar = 500 
µm.  (C) Dot blot experiments indicate that collagen strongly partitions to the interface of a 






Figure 6.2:  Characterization of aqueously-processed DEX-rich collagen.  (A) Scanning electron 
micrograph reveals that ATPS-collagen has a fiber size of 70 ± 24 nm, consistent with standard 
collagen fiber sizes.  (B) MC3T3 cells actively remodel the collagen matrix.  (C) Droplet 
diameter scales with droplet volume producing near-hemispherical domes on either tissue culture 
polystyrene or a monolayer of HEK 293 cells as a substrate (produced in 6% PEG solution).  
Droplet diameter is also influenced by (D) concentration of PEG in the surrounding media (5 µl 
droplets), and (E) concentration of collagen in the microdroplet (1 µL droplets).  All values 







Figure 6.3:  Viability of cells within ATPS-collagen microdroplets, as measured by (A, B) 
Live/dead viability assays.  (C) Cell viability under neutralized and acidic conditions after 1 and 
24 hours.  Viability is maintained when the collagen-DEX droplet has been neutralized (n = 5).  
(D) Viability of cells encapsulated in small droplets formed under aqueous-two phase and air 
conditions demonstrate that viability is greatly improved under aqueous processing conditions, 
most likely due to rapid evaporation of liquid in the small droplets during the gelation time 
period (values reported as means ± standard deviation, n= 10; * p < 0.001, compared within the 










Figure 6.4:  Contraction of collagen microdroplets.  (A) Representative images of MC 3T3 cells 
contracting the collagen microdroplet over two days in culture.  (B) Confocal image showing cell 
spreading within the collagen matrix after 2 days in culture.  Scale bar = 1 mm. (C) Human 
embryonic kidney (HEK293), mouse fibroblast (NIH 3T3) and mouse pre-osteoblast (MC 3T3) 
at densities of 1x106 ml-1 reduce the droplet area of collagen at distinctly different rates (n = 3; 





Figure 6.5:  Characterization of contraction in collagen microdroplets.  (A) Comparison of 
MC3T3 contraction of ATPS-collagen microdroplets against the conventional collagen 
contraction assay reveals that baseline percent contraction is independent of droplet or assay 
volume (n = 7-8 for ATPS; n = 3 for conventional assays).  (B) Collagen droplet contraction 
rates depend on cell density, (C) concentration of PEG in the surrounding media (at cell density 
of 1000 cells / µl), and (D) presence of soluble factors such as TGF-β1 (at cell density = 500 
cells / µl).  1, 5 and 10 ng/ml of TGF-β1 produced similar increases in contraction of the droplets 






Figure 6.6:  Miniaturization of droplets enables rapid diffusive transport through the collagen 
matrix.  (A) Simulations indicate that diffusive transport enables equilibration of the TGF-β1 
molecule (MW 25 kDa) within 1 hour, as compared to the conventional collagen contraction 
assay.  Scale bar = 1 mm.  (B) Percent equilibrium concentration at the base of the collagen 
droplets over time.  Conventional assays require ~24 hours to completely equilibrate to added 
concentrations of TGF- β1.  (C)  Timed stimulation of ATPS-collagen and conventional collagen 
droplets with TGF-β1.  Small volume (5 µl droplets) of ATPS-collagen respond to 1 minute of 
stimulation with TGF-β1, as compared to conventional assays.  (D) Small droplet size also 
enables simple removal of soluble factors for pulsed stimulation experiments.  After 24 hours, 
collagen contraction is strongly inhibited by Latrunculin-A, but contraction is recovered if the 
surrounding media is changed (n = 7-8 for ATPS assays; n = 3 for conventional assays; * 






Figure 6.7:  Patterning contractile collagen microdroplets within existing live-cell culture 
environments.  (A) NIH 3T3 cells (green) are encapsulated within a collagen droplet formed over 
a layer of HEK 293 cells (red).  (B)  A monolayer of MCF10A cells prior to collagen patterning, 
stained for actin (green) and nuclei (blue).  Actin structures indicate a well-connected epithelial 
monolayer.  (C,D)  MC3T3 cells encapsulated in collagen (formed via ATPS) on the existing 
epithelial monolayer.  The original boundary of the collagen droplet is marked with a white 
dashed line.  Within four hours, the MC3T3 cells induce contraction of the gel, ripping the cell 
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